Document:

<Page>

                                                                    Exhibit 10.8

                         NEW COMMERCIALIZATION AGREEMENT

     This NEW COMMERCIALIZATION AGREEMENT (the "Agreement"), effective as of
January 1, 2003 (the "Effective Date"), is made by and between Fuso
Pharmaceutical Industries, Ltd., a corporation organized under the laws of
Japan, with a principal place of business at 3-11, 2-Chome, Morinomiya, Joto-ku
Osaka 536-8523 Japan and its registered head office at 7-10, 1-Chome,
Doshomachi, Chuo-ku, Osaka 541-0045 Japan ("Fuso"), and GenVec, Inc., a Delaware
corporation, with a principal place of business at 65 West Watkins Mill Road,
Gaithersburg, Maryland 20878 ("GenVec").

                                   BACKGROUND

     A.      GenVec has expertise in the field of gene therapy and is developing
novel, proprietary materials and methods for use in the treatment of human
cancer.

     B.      Fuso is in the business of developing manufacturing and
commercializing pharmaceuticals in Japan.

     C.      GenVec and Fuso established a collaborative relationship on
September 26, 1997 to conduct research and develop certain gene therapy products
for the treatment of human cancer, which Fuso shall have the right to
commercialize in the Territory (as defined below) and GenVec shall have the
right to commercialize outside the Territory.

     D.      GenVec and Fuso desire to extend such collaboration under the terms
and conditions of this Agreement.

     NOW THEREFORE, for and in consideration of the covenants, conditions, and
undertakings hereinafter set forth, it is agreed by and between the parties as
follows:

1.   DEFINITIONS

     1.1     INCORPORATION BY REFERENCE. For purposes of this Agreement, the
capitalized terms used in this Agreement which are not defined herein shall have
the meanings set forth in the Collaboration Agreement.

[*]=CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS. OMITTED TEXT IS INDICATED BY A "*".

<Page>

     1.2     "AFFILIATE" shall mean any corporation or other entity which is
directly or indirectly controlling, controlled by or under the common control of
a party hereto. For the purpose of this Agreement, "control" shall mean the
direct or indirect ownership of at least fifty percent (50%) of the outstanding
shares or other voting rights of the subject entity to elect directors, or if
not meeting the preceding, any entity owned or controlled by or owning or
controlling at the maximum control or ownership right permitted in the country
where such entity exists.

     1.3     "BIOLOGICAL LICENSE APPLICATION" or "BLA" shall mean the Japanese
equivalent of a Biological License Application, as defined in the U.S. Food,
Drug and Cosmetic Act and the regulations promulgated thereunder, and any
corresponding foreign application, registration or certification in the
Territory.

     1.4     "* VECTOR" shall mean either a * Vector or a * Vector, in either
case that incorporates the nucleic acid sequence for * and does not incorporate
any other nucleic acid sequence encoding a protein intended for or otherwise
conferring therapeutic benefit.

     1.5     "COLLABORATION AGREEMENT" shall mean that certain New Collaboration
Agreement entered by Fuso and GenVec of even date herewith.

     1.6     "COLLABORATION PRODUCT" shall mean a *-TNF Vector developed in the
Research Program intended for use in the Field which the Steering Committee has
designated as such pursuant to Section 2.4 of the Collaboration Agreement. In
addition, pursuant to Section 2.4 of the Collaboration Agreement, a Product
Configuration that is a * Vector also may be treated as a Collaboration Product.

     1.7     "CONFIDENTIAL INFORMATION" shall mean (i) any proprietary or
confidential information or material in tangible form disclosed hereunder that
is marked as "Confidential" at the time it is delivered to the receiving party,
(ii) proprietary or confidential information disclosed orally hereunder which is
identified as confidential or proprietary when disclosed and such disclosure of
confidential information is confirmed in writing within thirty (30) days by the
disclosing party, or (iii) was Confidential Information under that certain
Commercialization Agreement between the parties dated September 26, 1997 as that
term was defined therein.

     1.8     "* VECTOR" shall mean a replication-deficient adenovector that: (i)
has been *.

     1.9     "*-TNF VECTOR" shall mean a * Vector that incorporates the nucleic
acid sequence encoding TNFalpha and does not incorporate any other nucleic acid
sequence encoding a protein intended for or otherwise conferring therapeutic
benefit.

     1.10    "DEVELOPMENT PLAN" shall mean the written plan for development of a
particular Collaboration Product prepared pursuant to Section 2.4.2 of the
Collaboration Agreement.

     1.11    "FIELD" shall mean Gene Therapy for the treatment of human
cancer, *.

                                      - 2 -
<Page>

     1.12    "FUSO TECHNOLOGY" shall mean Fuso Patent Rights and Fuso Know-How:

             1.12.1 "FUSO PATENT RIGHTS" shall mean (i) all patents and patent
applications conceived and reduced to practice by Fuso alone, or Fuso and/or its
agents, in connection with this Agreement or the Collaboration Agreement or in
connection with the Past Research Program, and (ii) any divisions,
continuations, continuations-in-part, reissues, reexaminations, extensions or
other governmental actions which extend any of the subject matter of the patent
applications or patents in (i) above, and any substitutions, confirmations,
registrations or revalidations of any of the foregoing, in each case, which are
owned or controlled, in whole or part, by license, assignment or otherwise by
Fuso, to the extent Fuso has the right to license or sublicense, and subject to
any limitations of (a) such license, assignment or other grant to Fuso, and (b)
any license or sublicense granted by Fuso at any time to any other entity or
entities in the settlement of patent-related disputes (e.g., an actual or
potential patent interference or opposition, or patent infringement suit) or
otherwise materially relevant to Fuso's business. For the avoidance of doubt,
the Fuso Patent Rights shall not include Fuso Know-How or any Gene Therapy
Technology.

             1.12.2 "FUSO KNOW-HOW" shall mean confidential information and
materials, including, but not limited to, pharmaceutical, chemical, biological
and biochemical products, technical and non-technical data, and information
relating to the results of tests, assays, methods and processes, and drawings,
plans, diagrams, specifications and/or other documents containing said
information and data, discovered, developed or acquired by Fuso alone, or Fuso
and/or its agents, in connection with this Agreement or the Collaboration
Agreement or in connection with the Past Research Program, which Fuso has the
right to license or sublicense, and subject to any limitations of (a) such
license, assignment or other grant to Fuso, and (b) any license or sublicense
granted by Fuso at any time to any other entity or entities in the settlement of
patent-related disputes (e.g., an actual or potential patent interference or
opposition, or patent infringement suit) or otherwise materially relevant to
Fuso's business. For the avoidance of doubt, Fuso Know-How shall not include any
Fuso Patent Rights or any Gene Therapy Technology.

     1.13    "GENE THERAPY" shall mean the introduction of a nucleic acid
sequence encoding a protein intended for or otherwise conferring therapeutic
benefit into a person for therapeutic purposes (i) by in vivo introduction for
incorporation into cells of such person, or (ii) by ex vivo introduction into
cells for transfer into a person.

     1.14    "GENE THERAPY TECHNOLOGY" shall have the meaning set forth in
Section 7.1.2 below.

     1.15    "GENVEC TECHNOLOGY" shall mean GenVec Patent Rights, GenVec
Know-How and Gene Therapy Technology:

             1.15.1 "GENVEC PATENT RIGHTS" shall mean (i) all patents and patent
applications listed on Exhibit A hereto, or conceived and reduced to practice by
GenVec alone, or GenVec and/or its agents in connection with this Agreement or
the Collaboration Agreement or in connection with the Past Research Program, and
(ii) any divisions, continuations, continuations-in-part, reissues,

                                      - 3 -
<Page>

reexaminations, extensions or other governmental actions which extend any of the
subject matter of the patent applications or patents in (i) above, and any
substitutions, confirmations, registrations or revalidations of any of the
foregoing, in each case, which are owned or controlled, in whole or part, by
license, assignment or otherwise by GenVec, to the extent GenVec has the right
to license or sublicense, and subject to any limitations of (a) such license,
assignment or other grant to GenVec, and (b) any license or sublicense granted
by GenVec at any time to any other entity or entities in the settlement of
patent-related disputes (e.g., an actual or potential patent interference or
opposition, or patent infringement suit) or otherwise materially relevant to
GenVec's business. For the avoidance of doubt, the GenVec Patent Rights shall
not include GenVec Know-How.

             1.15.2 "GENVEC KNOW-HOW" shall mean confidential information and
materials, including, but not limited to, pharmaceutical, chemical, biological
and biochemical products, technical and non-technical data, and information
relating to the results of tests, assays, methods and processes, and drawings,
plans, diagrams, specifications and/or other documents containing said
information and data, discovered, developed or acquired by GenVec alone, or
GenVec and/or its agents, in connection with this Agreement or the Collaboration
Agreement or in connection with the Past Research Program, which GenVec has the
right to license or sublicense, and subject to any limitations of (a) such
license, assignment or other grant to GenVec, and (b) any license or sublicense
granted by GenVec at any time to any other entity or entities in the settlement
of patent-related disputes (e.g., an actual or potential patent interference or
opposition, or patent infringement suit) or otherwise materially relevant to
GenVec's business. For the avoidance of doubt, GenVec Know-How shall not include
any GenVec Patent Rights.

     1.16    "* VECTOR" shall mean a replication-deficient adenovector that has
been *.

     1.17    "JOINT TECHNOLOGY" shall mean the Joint Patent Rights and Joint
Know-How.

             1.17.1 "JOINT PATENT RIGHTS" shall mean (i) all patents and patent
applications conceived and reduced to practice jointly by Fuso (and/or its
agents) and GenVec (and/or its agents) in connection with this Agreement or the
Collaboration Agreement or in connection with the Past Research Program, and
(ii) any divisions, continuations, continuations-in-part, reissues,
reexaminations, extensions or other governmental actions which extend any of the
subject matter of the patent applications or patents in (i) above, and any
substitutions, confirmations, registrations or revalidations of any of the
foregoing. For the avoidance of doubt, the Joint Patent Rights shall not include
the Joint Know-How or any Gene Therapy Technology.

             1.17.2 "JOINT KNOW-HOW" shall mean confidential information and
materials, including, but not limited to, pharmaceutical, chemical, biological
and biochemical products, technical and non-technical data, and information
relating to the results of tests, assays, methods and processes, and drawings,
plans, diagrams, specifications and/or other documents containing said
information and data, discovered, developed or acquired jointly by Fuso (and/or
its agents), and GenVec (and/or its agents), in connection with this Agreement
or the Collaboration Agreement or in connection with the Past Research Program.
For the avoidance of doubt, the Joint Know-How shall not include the Joint
Patent Rights or any Gene Therapy Technology.

                                      - 4 -
<Page>

     1.18    "MHLW" shall mean the Japanese Ministry of Health, Labour and
Welfare, or any corresponding foreign registration or foreign regulatory
authority in the Territory.

     1.19    "NET SALES" shall mean the gross revenue accrued by Fuso or its
Affiliates or Sublicensees for all Collaboration Products sold by Fuso and its
Affiliates and Sublicensees in arm's length sales to bona fide independent third
parties, and for any and all services related to the Collaboration Products
performed by or on behalf of Fuso or its Affiliates and Sublicensees, *. Net
Sales shall also include *.

In the case of * of products or services which include Collaboration Products,
Fuso may with notice to GenVec * the bona fide list price of a Collaboration
Product by the average percentage * of all products of Fuso and/or its
Affiliates or Sublicensees in a particular "bundle," calculated as follows:

                         *

where A equals the *, and B equals the * in such "bundle." Fuso shall provide
GenVec documentation, reasonably acceptable to GenVec, establishing such average
* with respect to each "bundle." If Fuso cannot so establish the average * of a
"bundle," Net Sales shall be based on the * list price of the Collaboration
Product in the "bundle." If a Collaboration Product in a "bundle" is not sold
separately and no bona fide list price exists for such Collaboration Product,
the parties *.

     1.20    "PAST RESEARCH PROGRAM" shall mean the "Research Program" under
that certain Collaboration Agreement between the parties dated September 26,
1997 as that term is defined therein.

     1.21    "PRODUCT CONFIGURATION" shall mean any potential product for use in
the Field containing a combination of one or more nucleic acid sequences
encoding a protein intended for or otherwise conferring therapeutic benefit and
other elements (e.g., a gene delivery vehicle and/or a gene expression
cassette).

     1.22    "RETAINED TERRITORY" shall mean, on a Collaboration
Product-by-Collaboration Product basis, Japan, Korea and Taiwan until the
earlier of (i) * with respect to a particular Collaboration Product, or (ii) *,
and thereafter shall have the same meaning as Territory with regard to such
Collaboration Product.

     1.23    "STEERING COMMITTEE" shall have the meaning set forth in Section
2.2.1 in the Collaboration Agreement.

     1.24    "SUBLICENSEE" shall mean a third party to whom Fuso has granted a
license or sublicense under the GenVec Technology or Joint Technology to make,
use and/or sell a Collaboration Product subject to Section 2.2 below. As used in
this Agreement, Sublicensee shall also include a third party to whom Fuso has
granted the right to distribute the Collaboration Product, provided that such
third party has the responsibility for marketing and/or promotion of the

                                      - 5 -
<Page>

Collaboration Product within the territory for which such distribution rights
are granted. For the avoidance of doubt, wholesellers or retailers who do not
take such responsibility shall not be deemed as Sublicensees. Furthermore,
* shall not be Sublicensees.

     1.25    "TERRITORY" shall mean Japan, and, where the option set forth in
Section 5.2.1 is exercised by Fuso, Korea and/or Taiwan, as the case may be.

     1.26    "TNFERADE" shall mean an anti-cancer agent which (i) is the GV11
Vector incorporating a nucleic acid sequence encoding TNFalpha presently
known as TNFerade(TM) (Ad.egr.TNF.11D) or (ii) comprises another replication
deficient adenovector, that is not a * Vector, and the nucleic acid sequence
encoding TNFalpha and is under development or being commercialized at any
time during the term of this Agreement by GenVec and/or its other
collaborators as an alternative to TNFerade(TM).

     1.27    "VALID CLAIM" shall mean a claim of a pending patent application or
a claim of an issued and unexpired patent within the GenVec Technology or Joint
Patent Rights which has not been held unpatentable, invalid or unenforceable by
a court or other government agency of competent jurisdiction in an unappealed or
unappealable decision and has not been admitted to be invalid or unenforceable
through reissue, re-examination, disclaimer or otherwise; provided, however,
that if the holding of such court or agency is later reversed by a court or
agency with appropriate authority, the claim shall be reinstated as a Valid
Claim with respect to Net Sales accruing after the date of such reversal.

2.   LICENSE GRANTS

     2.1     COMMERCIALIZATION LICENSES TO FUSO. Subject to the terms and
conditions of this Agreement, GenVec hereby grants to Fuso an exclusive,
royalty-bearing license under the GenVec Technology and GenVec's interest in the
Joint Technology, to make (subject to Article 6), have made (subject to Section
2.2.2) use, sell and otherwise commercialize Collaboration Products for all uses
in the Field in the Territory.

     2.2     SUBLICENSES AND *.

             2.2.1  SUBLICENSEES. Fuso may sublicense the rights to make, use
and/or sell granted in Section 2.1 to third parties, with the prior written
consent of GenVec, which consent shall not be unreasonably withheld. Fuso may
sublicense the rights granted in Section 2.1 to make Collaboration Products to
Affiliates of Fuso without the consent of GenVec, provided that such sublicense
shall remain in effect for only so long as such entity remains an Affiliate of
Fuso. Each sublicense granted by Fuso shall be consistent with all the terms and
conditions of this Agreement. Fuso shall remain responsible to GenVec for all of
each such Sublicensee's applicable financial and other obligations under this
Agreement.

             2.2.2  *. Subject to Article 6, Fuso may have Collaboration
Products * only to Fuso, its Affiliates or permitted Sublicensees; provided
that (i) such * agree in writing to be bound by the confidentiality
obligations set forth in

                                      - 6 -
<Page>

Article 9 hereof as if they were a party to this Agreement, (ii) Fuso shall
notify the name and financial strength of each * to GenVec prior to the
commencement of the *, and (iii) Fuso shall remain responsible to GenVec for
any failure by * to conform to such obligation.

     2.3     OTHER LICENSES.

             2.3.1  GENE THERAPY TECHNOLOGY. In the event that Fuso desires to
*, Fuso shall notify GenVec, and the parties agree to negotiate in good faith
for a period of *, or such longer period as the parties may agree, the terms and
conditions on which GenVec would grant such a license to Fuso; provided,
however, in no event shall GenVec be obligated to negotiate or grant a license
for any * which might compete with *.

             2.3.2  FUSO TECHNOLOGY. Subject to the provisions of Section 7.1.2
below, Fuso hereby grants to GenVec the following licenses under the Fuso
Technology and Fuso's interest in the Joint Technology:

                    (a)  a * license to make, have made, use, sell and otherwise
commercialize Collaboration Products, *; and

                    (b)  a * license, subject to Section 5.6.2 below, to make,
have made, use, sell and otherwise commercialize Collaboration Products *; and

                    (c)  a * license to make, have made, use, sell, research and
otherwise commercialize products *; and

                    (d)  *, a * license to make, have made, use, sell and
otherwise commercialize products *. The financial obligations due Fuso with
respect to the license in this Section 2.3.2(d) shall be negotiated in good
faith by the parties; provided, in the event the parties are unable to agree,
such terms shall be established pursuant to Article 12.

             2.3.3  GenVec may sublicense the rights granted in Section 2.3.2 to
third parties, without the prior written consent of Fuso. Each sublicense
granted by GenVec shall be consistent with all the terms and conditions of this
Agreement and no Sublicensee may grant further sublicenses without the prior
written consent of GenVec. GenVec shall remain responsible to Fuso for all of
each such sublicensee's applicable financial and other obligations under this
Agreement.

     2.4     COVENANT NOT TO SUE. In partial consideration for the grant of
rights hereunder, Fuso agrees not to enforce against GenVec or its Affiliates
any patent right owned or controlled by Fuso or its Affiliates during the term
of this Agreement that GenVec or its Affiliates may infringe in practicing the
inventions claimed in the GenVec Patent Rights.

     2.5     RETAINED RIGHTS. It is understood and agreed that GenVec shall
retain the exclusive right (i) to make, have made, use, sell and otherwise
commercialize the Collaboration Products for

                                      - 7 -
<Page>

all uses within the Field outside the applicable Retained Territory; (ii)
subject to Sections 2.4.3, 2.4.4, and 2.4.5 of the Collaboration Agreement, to
make, have made, use, sell and otherwise commercialize the Collaboration
Products for use outside the Field, both in and outside the applicable Retained
Territory; (iii) to make, have made, use and sell Collaboration Products to Fuso
in connection with the activities conducted by GenVec pursuant to this
Agreement, unless and until Fuso assumes manufacture of the Collaboration
Products pursuant to Article 6, and (iv) to practice any method, process or
procedure within, and otherwise develop, exploit and/or commercialize the Gene
Therapy Technology.

     2.6     NO IMPLIED LICENSES. Fuso acknowledges that the licenses granted by
GenVec in Section 2.1 are limited to the Field and the applicable Retained
Territory. No rights or licenses with respect to the GenVec Technology or the
Fuso Technology or other intellectual property owned by GenVec or Fuso are
granted or shall be deemed granted hereunder or in connection herewith, other
than those rights expressly granted in this Agreement or the Collaboration
Agreement.

3.   PAYMENTS

     3.1     ROYALTIES.

             3.1.1  ROYALTIES ON NET SALES. In partial consideration of the
rights granted under the GenVec Patent Rights and GenVec Know-How in this
Agreement, Fuso shall pay running royalties to GenVec equal to * percent (*%) of
Net Sales of Collaboration Products by Fuso and its Affiliates and Sublicensees.

             3.1.2  * ROYALTY; * SALES. * shall be payable under Section 3.1.1
above with respect to sales of the Collaboration Product among Fuso, its
Affiliates and Sublicensees for resale. In no event shall * be due GenVec
hereunder with respect to any Collaboration Product.

             3.1.3  ROYALTY TERM. The obligation of Fuso to pay royalties
under this Article 3 shall continue for each Collaboration Product on a
Collaboration Product-by-Collaboration Product and country-by-country basis,
until the later of (i) such time as there are no Valid Claims covering the
manufacture, sale or use of such Collaboration Product in such country, or
(ii) * from the first commercial sale of such Collaboration Product in such
country.

             3.1.4  *. It is understood and agreed that regardless of any
offsets to which Fuso is entitled, the royalty payments made to GenVec under
Section 3.1.1 in any quarter * by Fuso and its Affiliates and Sublicensees in
the applicable quarter.

             3.1.5  THIRD PARTY ROYALTIES. Except as provided in Section 2.3.2
of the Collaboration Agreement, * shall be responsible for the payment of any
royalties, license fees and milestone and other payments due to third parties
under licenses or similar agreements necessary for the manufacture, use or sale
of Collaboration Products in the Territory. *.

                                      - 8 -
<Page>

     3.2     INITIAL PAYMENTS. Within thirty (30) days following the first
occurrence in * with respect to each Collaboration Product, Fuso shall pay to
GenVec * dollars ($*). Fuso shall promptly notify GenVec upon the achievement of
the foregoing milestone with respect to each Collaboration Product.

4.   PAYMENTS; BOOKS AND RECORDS

     4.1     ROYALTY REPORTS AND PAYMENTS. After the first commercial sale by
Fuso or its Affiliates or Sublicensees of a Collaboration Product for which
royalties are payable under Article 3, Fuso shall make quarterly written reports
to GenVec within thirty (30) days after the end of each calendar quarter,
stating in each such report, by country, the number, description and aggregate
Net Sales of such Collaboration Product sold during the calendar quarter.
Simultaneously with the delivery of each such report, Fuso shall pay to GenVec
the total royalties, if any, due to GenVec for the period of such report. If no
royalties are due, Fuso shall so report.

     4.2     PAYMENT METHOD; LATE PAYMENTS. All amounts due GenVec hereunder
shall be paid in U.S. dollars by wire transfer in immediately available funds to
an account designated by GenVec. Any payments or portions thereof due hereunder
which are not paid on the date such payments are due under this Agreement shall
bear interest at a rate equal to the lesser of prime rate as reported by the
Chase Manhattan Bank, New York, plus * percent (*%) per year, or the maximum
rate permitted by law, calculated on the number of days such payment is
delinquent, compounded monthly.

     4.3     CURRENCY CONVERSION. If any other currency conversion shall be
required in connection with the calculation of royalties hereunder, such
conversion shall be made using the exchange rate for conversion of the foreign
currency into U.S. Dollars, quoted for current transactions for buying U.S.
dollars, as reported in The Wall Street Journal for the last business day of the
calendar quarter to which such payment pertains.

     4.4     RECORDS; INSPECTION. Fuso shall keep (and cause its Affiliates and
its Sublicensees to keep) complete, true and accurate books of account and
records for the purpose of determining the royalty amounts payable under Article
3. Such books and records shall be kept reasonably accessible for at least three
(3) years following the end of the calendar quarter to which they pertain. Such
records will be open for inspection during such three (3) year period by a
representative or agent of GenVec for the purpose of verifying the royalty
statements. Such inspections may be made no more than once each calendar year,
at reasonable times mutually agreed by Fuso and GenVec. GenVec's representative
or agent will be obliged to execute a reasonable confidentiality agreement prior
to commencing any such inspection. GenVec shall bear the costs and expenses of
inspections conducted under this Section 4.4 unless a variation or error
producing an underpayment in royalties payable exceeding * percent (*%) of the
amount payable for any quarter is established in the course of any such
inspection, whereupon all costs relating to the inspection and any unpaid
amounts that are discovered will be paid by Fuso, together with interest on such
unpaid amounts at the rate specified in Section 4.2 above.

     4.5     WITHHOLDING TAXES.

                                      - 9 -
<Page>

             4.5.1  ROYALTIES. Any payments due GenVec by Fuso pursuant to
Section 3.1 above shall be made after deduction for any withholding taxes or
similar governmental charge ("Withholding Tax") due thereon. Fuso shall provide
GenVec a certificate evidencing payment of any such Withholding Taxes.
Notwithstanding the foregoing, if such payments by GenVec would reduce the
royalty received by GenVec on any Net Sales below * percent (*%) of Net Sales
(after such withholding or other governmental charge), then Fuso shall pay to
GenVec any such additional amounts as may be necessary to provide GenVec a
royalty of no less than * percent (*%) of such Net Sales (after such withholding
or other governmental charge). In such event, if GenVec receives a tax credit
from the U.S. Government for any such additional payments, then GenVec shall
promptly notify Fuso and reimburse Fuso for such amount. GenVec agrees to use
reasonable efforts to obtain any available tax credit.

             4.5.2  MILESTONES. All payments required to be made to GenVec
pursuant to Section 3.2 shall be made after deduction for any withholding taxes
or similar governmental charge required by applicable law. Fuso shall promptly
inform GenVec of the amount and basis of any such deduction, and provide GenVec
a certificate evidencing payment of any such Withholding Taxes.

     4.6     SALES TAXES. Any sales taxes (such as consumption tax or value
added tax), use taxes, transfer taxes, duties or similar governmental charges
required to be paid in connection with the transfer to Fuso of any Collaboration
Products manufactured by GenVec hereunder shall be the sole responsibility of
Fuso. In the event that GenVec is required to pay any such amounts, Fuso shall
promptly remit payment to GenVec of such amounts.

5.   COMMERCIALIZATION

     5.1     COLLABORATION PRODUCT DEVELOPMENT BY FUSO. Except as expressly
provided otherwise in this Agreement, Fuso shall be responsible for all costs of
conducting development of Collaboration Product(s) in the Territory in
accordance with the applicable Development Plan(s), including, without
limitation expenses incurred in conducting clinical trials (e.g., clinical
trials in the Territory, and clinical trials conducted outside the Territory
which provide data for regulatory approvals in the Territory). In addition, Fuso
shall be responsible, at its sole expense, for all commercialization of such
Collaboration Product(s) in the Field in the Territory so long as Fuso retains
rights thereto under this Agreement. During the term of this Agreement, Fuso
shall keep GenVec fully informed of its activities subject to this Agreement
and, in addition, on or before January 31 of each year, Fuso shall provide
GenVec with a written report detailing such events and activities. When a
registration package requesting approval for commercial sale of any
Collaboration Product is first filed in any country within the Territory, and
when approval is received therefore, Fuso will immediately notify GenVec in
writing.

     5.2     DUE DILIGENCE.

             5.2.1  OPTION. Fuso shall have the option to add both or either of
Korea and Taiwan to the Territory by notice to GenVec identifying the pertinent
country(ies) and Collaboration Product.

                                     - 10 -
<Page>

Such option must be exercised with respect to a particular Collaboration Product
no later than the *. If Fuso fails to exercise such option with respect to a
particular Collaboration Product within the applicable period, or Fuso's rights
terminate in Japan with respect to a particular Collaboration Product prior to
the date that Fuso exercises its option for such Collaboration Product, then
Fuso shall lose its option with respect to such Collaboration Product in Korea
and Taiwan.

             5.2.2  REASONABLE EFFORTS. Fuso shall use all reasonable efforts
to: (i) obtain regulatory approvals to market Collaboration Product(s) in each
country the Territory, and (ii) after obtaining regulatory approvals for such
Collaboration Product(s), launch such Collaboration Product(s) in each country
in the Territory. Upon the launching of such Collaboration Product(s), Fuso
shall use reasonable efforts to promote and meet the market demand therefor in
the respective country(ies). In connection therewith, Fuso shall use efforts not
less than those efforts Fuso makes with respect to its own pharmaceutical
products of comparable commercial potential, stage of development and patent
protection.

             5.2.3  LACK OF DILIGENCE. In the event that Fuso fails to use
reasonable efforts to exercise its diligence obligations under Section 5.2.2
with respect to a particular Collaboration Product as to a particular country of
the Territory, GenVec may terminate this Agreement with respect to such
Collaboration Product as to such country in accordance with Section 11.2. In
such event, GenVec shall thereafter have the exclusive rights to commercialize
such Collaboration Product in the said country, alone or with third parties.

             5.2.4  LICENSES. In the event that any of Fuso's rights terminate
with respect to a particular Collaboration Product pursuant to Section 5.2.3
above, at GenVec's request, Fuso shall grant to GenVec an exclusive (even as to
Fuso), fully-paid, royalty-free license, with the right to sublicense, under
Fuso's interest in any Joint Technology and Fuso Technology necessary or useful
to make, have made, import, use, offer for sale, sell and otherwise
commercialize such Collaboration Products in the Field in the said country.

     5.3     REGULATORY FILINGS.

             5.3.1  USE OF DOCUMENTS. Each party and its Affiliates, and,
subject to such party's obligations to third parties, its licensees and
sublicensees, shall have the right, without charge, to refer to, access, cross
reference, and use documents relating to each Collaboration Product filed by a
party or its Affiliates, its licensees or Sublicensees with regulatory entities
with respect to activities conducted in connection with the Research Program,
including clinical studies and other supporting information, and any written
communications to and with the MHLW, FDA and other comparable regulatory bodies.

             5.3.2  OUTSIDE THE RESEARCH PROGRAM. Subject to its obligations to
third parties, each party and its Affiliates, licensees and sublicensees shall
have the right to refer to, access, cross reference, and use documents filed
with regulatory entities relating to each Collaboration Product, filed by a
party or its Affiliates or Sublicensees in agreed jurisdictions, with respect to
activities conducted outside the Research Program, including clinical studies
and other supporting

                                     - 11 -
<Page>

information, and any written communications to and with the MHLW, FDA and other
comparable regulatory bodies.

     5.4     NO OTHER GENE THERAPY PRODUCTS. Except as specifically provided in
this Agreement or otherwise agreed in writing, neither Fuso nor its Affiliates
or Sublicensees shall commercialize any Gene Therapy product studied in the
Research Program, except as a Collaboration Product in accordance with this
Agreement, which is identical or substantially similar to a Product
Configuration studied in the Research Program. As used herein, "substantially
similar" shall mean a product which contains a gene studied in the Research
Program (or a fragment or derivative or homolog thereof), in each case, which
encodes a peptide or nucleic acid with biological activity substantially
equivalent to such gene (or fragment or homolog or derivative).

     5.5     GENVEC COMMERCIALIZATION. Subject to Sections 2.3.1(a) and 2.4.2 of
the Collaboration Agreement, GenVec shall be responsible, at its sole expense,
for conducting all development of any Collaboration Product outside the Field,
both in and outside the Territory (including, without limitation, clinical
trials), and all commercialization of such Collaboration Product outside the
Field, both in and outside the Territory.

     5.6     NON-COMPETE.

             5.6.1  Fuso shall not, directly or indirectly, develop or
commercialize, or enter into any collaboration agreement or other agreement with
any third party for the manufacture, development or commercialization, of any
product comprising a nucleic acid sequence encoding TNF or * or a modification
or derivative thereof during the period beginning on the Effective Date and
ending the later of * after the end of the Agreement Term or the termination or
expiration of the Commercialization Agreement, other than a Collaboration
Product developed and commercialized pursuant to this Agreement and the
Collaboration Agreement.

             5.6.2  GenVec shall not in the Field in the Territory, directly or
indirectly, develop or commercialize, or enter into any collaboration agreement
or other agreement with any third party for the manufacture, development or
commercialization of: (i) any product that is exactly the same as a
Collaboration Product during the Agreement Term and the term of the
Commercialization Agreement, (ii) any product that is a * Vector that
incorporates a nucleic acid sequence encoding TNFalpha or * or is a * Vector
that incorporates a nucleic acid sequence encoding * during the period beginning
on the Effective Date and ending the earlier of the expiration or termination of
the Collaboration Agreement or December 31, 2005 or, in the case of a product
that incorporates a nucleic acid sequence encoding *, the earlier of such dates
and the date Fuso ceases activities with respect to the * Vector currently under
investigation by Fuso as a potential Collaboration Product, (iii) any product
that is a * Vector that incorporates a nucleic acid sequence encoding TNFalpha,
or is a version of TNFerade that is engineered for regional/systemic
application(s), with respect to the same indication(s) for which a Collaboration
Product that incorporates a nucleic acid sequence encoding TNFalpha is being
developed and commercialized in the Field in the Territory during the period
beginning on * and ending *, and (iv) any product that is a * Vector that
incorporates a nucleic acid sequence encoding * or is a * Vector that
incorporates a nucleic acid sequence encoding *, with

                                     - 12 -
<Page>

respect to the same indication(s) for which a Collaboration Product that
incorporates a nucleic acid sequence encoding * is being developed and
commercialized in the Field in the Territory during the period beginning on the
Effective Date and ending the expiration or termination of the Commercialization
Agreement, unless the Steering Committee after * determines that such product
has * such Collaboration Product; in each case other than a Collaboration
Product developed and commercialized pursuant to this Agreement and the
Collaboration Agreement.

     5.7     ACKNOWLEDGMENT. It is understood and agreed that the provisions of
Sections 2.4.3, 2.4.4, 2.4.5 and 2.4.6 of the Collaboration Agreement establish
certain limits on the development and commercialization activities of the
parties with respect to certain Product Configurations and Gene Therapy
products.

6.   *

     6.1     * .

             6.1.1  CLINICAL TRIALS IN THE TERRITORY. Fuso shall have the first
right, but not the obligation to *, on a Collaboration Product-by-Collaboration
Product basis, subject to GenVec's approval not to be unreasonably withheld.
GenVec's decision to approve or disapprove * shall be based on *. If Fuso elects
not to *, or GenVec does not approve of *, GenVec shall have the first right,
but not the obligation to *, on a Collaboration Product-by-Collaboration Product
basis, subject to Fuso's approval, not to be unreasonably withheld. Fuso's
decision to approve or disapprove * shall be based on *. In the event that
GenVec declines to *, or Fuso does not approve of the *, then, subject to
Section 6.1.2, Fuso may *, reasonably acceptable to GenVec, to *.

             6.1.2  *. If Fuso has * pursuant to Section 6.1.1 above, it will
require that such * only to Fuso, its Affiliates or permitted Sublicensees. In
addition (i) such * shall agree in writing to be bound by the confidentiality
obligations set forth in Article 9 hereof as if they were a party to this
Agreement, (ii) Fuso shall notify GenVec of the name and financial strength of
each * prior to the commencement of the *, and (iii) Fuso shall remain
responsible to GenVec for any failure by * to conform to such obligation.

             6.1.3  TRANSFER OF *. If Fuso * pursuant to Section 6.1.1 above,
the parties shall negotiate in good faith the * for the *, and shall cooperate
with each other in order that Fuso may * as soon as practicable; provided,
GenVec shall not be obligated to * which is subject to a contractual obligation
with a third party.

             6.1.4  * AGREEMENT. If Fuso * pursuant to Section 6.1.1, the
parties shall promptly negotiate in good faith the terms of a * agreement which
shall set forth the terms and conditions of such *. In the event the parties
fail to enter into a written * agreement within * from the date that Fuso
provides GenVec notice of its wish to enter into such a * agreement, or such
longer period as the parties may agree, then GenVec shall have no obligation
to *.

                                     - 13 -
<Page>

             6.1.5  *. At GenVec's request, Fuso shall, at its option, *, on
terms to be agreed in good faith by the parties.

             6.1.6  *. At GenVec's request, the parties agree to conduct good
faith negotiations regarding the appointment of * of other agreed GenVec
products; provided, however that GenVec shall be under no obligation to *, and
Fuso shall be under no obligation to *, unless the parties mutually agree on
terms and conditions governing such *.

     6.2     FUSO RESPONSIBILITIES. If Fuso undertakes to *, Fuso shall be *.
All Collaboration Products * will conform with all *. Fuso shall keep GenVec
fully informed of the * relating thereto and GenVec shall have the right on
reasonable prior notice to visit the * during ordinary business hours and review
any relevant records relating to *(excluding records relating to the *).

     6.3     POST TERMINATION MANUFACTURING. Following the termination of this
Agreement due to the expiration of Fuso's royalty obligations in all countries
in the Territory pursuant to Section 11.1 due to completion of the full payment
term, Fuso shall have the right to make and have made Collaboration Products.

7.   INTELLECTUAL PROPERTY

     7.4     OWNERSHIP OF INVENTIONS.

             7.4.1  RESEARCH PROGRAM TECHNOLOGY. Subject to Section 7.1.2 below,
(i) title to all inventions and intellectual property made solely by GenVec
employees or its agents in connection with the Research Program without
inventive contribution by Fuso employees or its agents shall be owned by GenVec;
(ii) title to all inventions and intellectual property made solely by Fuso
employees or its agents in connection with the Research Program without
inventive contribution by GenVec employees or its agents shall be owned by Fuso;
and (iii) title to all inventions and intellectual property made jointly by
employees or the agents of Fuso and GenVec in connection with the Research
Program, shall be jointly owned by GenVec and Fuso.

             7.4.2  GENE THERAPY TECHNOLOGY. Notwithstanding Section 7.1.1
above, GenVec shall own all inventions and intellectual property made in
connection with this Agreement during the term of this Agreement (i) solely by
GenVec employees or agents or jointly by employees or agents of Fuso and GenVec
that relate to the introduction of genetic material of nucleic acid composition,
or a portion thereof, into a vector and/or cell to create a desired effect or
identify an unknown effect, including techniques and processes relating to the
manufacture, evaluation and use thereof, and methods relating to all of the
foregoing, (ii) by either or both of the parties and/or their agents that relate
to or are made using materials transferred to Fuso by or on behalf of GenVec, or
(iii) by either or both of the parties and/or their agents that relate to or are
made using Collaboration Products, * Vector, * Vector, *-TNF Vector or * Vector
(collectively, "Gene Therapy Technology"). Fuso hereby assigns to GenVec all its
right, title and interest it may otherwise hold in or to such Gene Therapy
Technology and any patent applications or patents relating thereto. Fuso shall,
at the request of GenVec, execute, and deliver or cause to be delivered, all
such consents, documents or

                                     - 14 -
<Page>

further instruments of assignment or transfer, and take or cause to be taken all
such actions GenVec reasonably deems necessary or desirable in order for GenVec
to obtain the full benefits of the assignment herein.

             7.4.3  INVENTORSHIP. Inventorship and rights of ownership of
inventions and other intellectual property rights conceived and/or reduced to
practice in connection with the Research Program shall be determined in
accordance with the patent and other intellectual property laws of the United
States or Maryland, as applicable, as long as the laws of the Territory permit
application of such laws. Subject to the licenses granted in Article 2, except
as expressly provided in this Agreement, it is understood that neither party
shall have any obligation to account to the other for profits, or to obtain any
approval of the other party to license, permit sublicensing, or exploit a Joint
Technology for applications outside of the Field by reason of joint ownership of
any such intellectual property.

     7.5     PATENT PROSECUTION

             7.5.1  SOLE INVENTIONS. Fuso or GenVec, as the case may be, shall,
be responsible for preparing, filing, prosecuting and maintaining of the patent
applications and patents, solely owned by it, worldwide in such countries as it
deems appropriate, and conducting any interferences, reexaminations, reissues,
oppositions or requests for patent term extensions relating to the Fuso
Technology or GenVec Technology (respectively), using counsel of its choice, at
its expense; provided, such expenses may be included in the Research Program
funding described in Section 2.3 of the Collaboration Agreement.

             7.5.2  PATENT RIGHTS FOR JOINT TECHNOLOGY.

                    (a)  The parties will cooperate to file, prosecute and
maintain patent applications covering the Joint Technology(ies) in the United
States, European Union (in Europe through a European Patent Convention
application) and Japan (collectively, the "Core Countries") and other countries
agreed by the parties. The parties shall agree which party shall be responsible
for conducting such activities with respect to a particular Joint Technology.
The party conducting such activities shall keep the other party fully informed
as to the status of such patent matters, including, without limitation, by
providing the other party the opportunity, at the other party's expense, to
review and comment on any documents relating to the Joint Technology which will
be filed in any patent office at least thirty (30) days before such filing, and
promptly providing the other party copies of any documents relating to Joint
Technology which the party conducting such activities receives from such patent
offices, including notice of all interferences, reissues, reexaminations,
oppositions or requests for patent term extensions. The parties will share
equally all expenses and fees associated with the filing, prosecution, issuance
and maintenance of any patent application and resulting patent for a Joint
Technology in the Core Countries and other agreed countries and such amounts
shall be included within the Research Program funding described in Section 2.3
of the Collaboration Agreement.

                                     - 15 -
<Page>

                    (b)  In the event that either party wishes to seek patent
protection with respect to any Joint Technology outside the Core Countries, it
shall notify the other party hereto. If both parties wish to seek patent
protection with respect to such Joint Technology in such country or countries,
activities shall be subject to Section 7.2.2(a) above. If only one party wishes
to seek patent protection with respect to such Joint Technology in such country
or countries, it may file, prosecute and maintain patent applications and
patents with respect thereto, at its own expense. In any such case, the party
declining to participate in such activities shall not grant any third party a
license under its interest in the applicable Joint Technology in the applicable
country or countries without the prior written consent of the other party, which
consent shall not be unreasonably withheld.

     7.6     ENFORCEMENT.

             7.6.1  SOLELY OWNED TECHNOLOGY. Subject to 7.3.2 below, in the
event that any GenVec Technology or Fuso Technology (in this Section, both
referred to as "Technology") necessary for manufacture, use and sale of a
Collaboration Product is infringed or misappropriated by a third party in any
country in the Territory, or is subject to a declaratory judgment action arising
from such infringement in such country, Fuso or GenVec, as the case may be,
shall promptly notify the other party hereto. The party which owns or controls
such Technology (the "Owner") shall have the initial right (but not the
obligation) to enforce such Technology, or defend any declaratory judgment
action with respect thereto, at its expense. In the event that the Owner fails
to initiate a suit to enforce such Technology against a commercially significant
infringement in the Field by a third party in any jurisdiction in the Territory
within * of a request by the other party (the "Licensee") to do so, Licensee
may, subject to the Owner's agreements with third parties, initiate such suit in
the name of the Owner of such Technology against such infringement, at the
expense of such Licensee. The party involved in any such claim, suit or
proceeding, shall keep the other party hereto reasonably informed of the
progress of any such claim, suit or proceeding. Any recovery by such party
received as a result of any such claim, suit or proceeding shall be used first
to reimburse such party for all expenses (including attorneys and professional
fees) incurred in connection with such claim, suit or proceeding and if the
party initiating the suit was the owner of the subject Technology, all of the
remainder shall be retained by such owner, and if the party initiating the suit
is the Licensee, * percent (*%) of the remainder shall be paid to the owner of
the subject Technology and * percent (*%) retained by the Licensee. If the
Licensee initiates such suit in the name of the Owner of such Technology against
such infringement, the Licensee shall not enter into any agreement which makes
any admission regarding (i) wrongdoing on the part the Owner, or (ii) the
invalidity, unenforceability or absence of infringement of the Owner's
Technology, without the prior written consent of the Owner, which consent shall
not be unreasonably withheld. The parties shall cooperate with each other in
connection with any such claim, suit or proceeding and shall keep each other
reasonably informed of all material developments in connection with any such
claim, suit or proceeding.

             7.6.2  JOINTLY OWNED TECHNOLOGY. Notwithstanding 7.3.1 above, in
the event that any technology that is jointly owned by GenVec and Fuso under
Section 7.1 of this Agreement is infringed or misappropriated by a third party,
Fuso and GenVec shall discuss whether, and, if so, how, to enforce such Joint
Technology or defend such Joint Technology in an infringement action,
declaratory judgment or other proceeding. In the event only one party wishes to
participate in such

                                     - 16 -
<Page>

proceeding, it shall have the right to proceed alone, at its expense, and may
retain any recovery; provided, at the request and expense of the participating
party, the other party agrees to cooperate and join in any proceedings in the
event that a third party asserts that the co-owner of such Joint Technology is
necessary or indispensable to such proceedings.

     7.7     INFRINGEMENT CLAIMS. If the manufacture, sale or use of any
Collaboration Product in the Territory pursuant to this Agreement results in any
claim, suit or proceeding alleging patent infringement against GenVec or Fuso,
such party shall promptly notify the other party hereto. If Fuso is not named as
a party in such a claim, suit or proceeding, Fuso may, at its own expense and
through counsel of its own choice, seek leave to intervene in such claim, suit
or proceeding. GenVec agrees not to oppose such intervention. If Fuso, and not
GenVec, is named as a party to such claim, suit or proceeding, Fuso shall have
the right to control the defense and settlement of such claim, suit or
proceeding, at its own expense, using counsel of its own choice, however GenVec,
at its own expense and through counsel of its own choice, may seek to intervene
if the claim, suit or proceeding relates to the commercialization of the
Collaboration Product in the Field, and in such event, Fuso agrees not to oppose
such intervention. If Fuso is named as a party and GenVec shall, at any time,
tender its defense to Fuso, then Fuso shall defend GenVec in such claim, suit or
proceeding, at Fuso's own expense and through counsel of its own choice, and
Fuso shall control the defense and settlement of any such claim, suit or
proceeding; provided, Fuso shall not enter into any agreement which makes any
admission regarding (i) wrongdoing on the part GenVec, or (ii) the invalidity,
unenforceability or absence of infringement of any GenVec Patent Rights or
patent claiming a Joint Technology, without the prior written consent of GenVec,
which consent shall not be unreasonably withheld. The parties shall cooperate
with each other in connection with any such claim, suit or proceeding and shall
keep each other reasonably informed of all material developments in connection
with any such claim, suit or proceeding.

8.   REPRESENTATIONS AND WARRANTIES

     8.1     WARRANTIES.

     8.1.1   GENVEC. GenVec warrants and represents to Fuso that (i) it has the
full right and authority to enter into this Agreement and grant the rights and
licenses granted herein; (ii) as of the Effective Date, except for the
interference proceedings pending in the U.S. Patent and Trademark Office, there
are no existing or threatened actions, suits or claims pending against it with
respect to the GenVec Technology or its right to enter into and perform its
obligations under this Agreement and (iii) it has not previously granted, and
will not grant during the term of this Agreement, any right, license or interest
in or to GenVec Technology or Joint Technology, or any portion thereof, which
are in conflict with the rights or licenses granted under this Agreement.

     8.1.2   FUSO. Fuso warrants and represents to GenVec that (i) it has the
full right and authority to enter into this Agreement, and (ii) it has not
previously granted, and will not grant during the term of this Agreement, any
right, license or interest in or to Fuso Technology or Joint Technology, or any
portion thereof, which are in conflict with the rights or licenses granted under
this Agreement.

                                     - 17 -
<Page>

     8.2     EFFECT OF REPRESENTATIONS AND WARRANTIES. It is understood that if
the representations and warranties under this Article 8 are not true and
accurate and GenVec or Fuso incurs liabilities, costs or other expenses as a
result of such falsity, GenVec or Fuso, as the case may be, shall indemnify,
defend and hold the other party harmless from and against any such liabilities,
costs or expenses incurred, provided that the indemnifying party receives prompt
notice of any claim against GenVec or Fuso, as the case maybe, resulting from or
related to such falsity, the cooperation of the indemnified party, as requested
in connection with any such claim, and the sole right to control the defense or
settlement thereof.

     8.2     DISCLAIMER OF WARRANTIES. GENVEC AND FUSO EXPRESSLY DISCLAIM ANY
WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE
CONFIDENTIAL INFORMATION, OR FUSO TECHNOLOGY OR GENVEC TECHNOLOGY, INCLUDING,
WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS
FOR A PARTICULAR PURPOSE, VALIDITY OF FUSO TECHNOLOGY OR GENVEC TECHNOLOGY,
PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES.

9.   CONFIDENTIALITY

     9.1     CONFIDENTIAL INFORMATION. Except as expressly provided herein, the
parties agree that the receiving party shall keep completely confidential and
shall not publish or otherwise disclose and shall not use for any purpose except
for the purposes contemplated by this Agreement any Confidential Information
furnished to it by the disclosing party hereto pursuant to this Agreement,
except that to the extent that it can be established by the receiving party by
competent proof that such Confidential Information:

             (a)    was already known to the receiving party, other than under
an obligation of confidentiality, at the time of disclosure;

             (b)    was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving party;

             (c)    became generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement;

             (d)    was independently developed by the receiving party without
reference to any information or materials disclosed by the disclosing party; or

             (e)    was subsequently disclosed to the receiving party by a
person other than a party without breach of any legal obligation to the
disclosing party.

                                     - 18 -
<Page>

     9.2     PERMITTED DISCLOSURES. Each party hereto may disclose the other's
Confidential Information to the extent such disclosure is reasonably necessary
in connection with the conduct of the Research Program activities to be
conducted at any academic institution approved by the Steering Committee, in
filing or prosecuting patent applications, prosecuting or defending litigation,
complying with applicable governmental regulations or otherwise submitting
information to tax or other governmental authorities, conducting clinical
trials, making a permitted sublicense, securing funding or otherwise exercising
its rights hereunder, provided that if a party is required to make any such
disclosure of another party's confidential information, other than pursuant to a
confidentiality agreement, it will give reasonable advance notice to the latter
party of such disclosure and, save to the extent inappropriate in the case of
patent applications, will use its best efforts to secure confidential treatment
of such information prior to its disclosure (whether through protective orders
or otherwise).

     9.3     NON-DISCLOSURE. Each of the parties hereto agrees not to disclose
to any third party the financial terms of this Agreement without the prior
written consent of each other party hereto, except to advisors, investors and
others on a need to know basis under circumstances that reasonably ensure the
confidentiality thereof, or to the extent required by law. Without limitation
upon any provision of this Agreement, each of the parties hereto shall be
responsible for the observance by its employees of the foregoing confidentiality
obligations. Notwithstanding the foregoing, the parties shall agree upon a press
release to announce the execution of this Agreement, together with a
corresponding Q&A outline for use in responding to inquiries about the
Agreement; thereafter, GenVec and Fuso may each disclose to third parties the
information contained in such press release and Q&A without the need for further
approval by the other.

10.  INDEMNIFICATION

     10.1    INDEMNIFICATION OF FUSO. GenVec shall indemnify and hold Fuso and
its Affiliates, and their respective directors, officers, employees, agents and
counsel, and the successors and assigns of the foregoing (the "Fuso
Indemnitees"), harmless from and against any and all liabilities, damages,
losses, costs or expenses (including reasonable attorneys' and professional fees
and other expenses of litigation and/or arbitration) resulting from a claim,
suit or proceeding brought by a third party against a Fuso Indemnitee, arising
from or occurring as a result of: (i) GenVec's conduct of the Research Program,
(ii) the development, manufacture, marketing and/or commercialization of any
Collaboration Product by GenVec or its Affiliates or licensees other than Fuso
and its Affiliates (including without limitation product liability claims), or
(iii) the failure of Collaboration Products manufactured by GenVec to meet the
relevant specifications, except, in each case, to the extent caused by the
negligence or willful misconduct of Fuso.

     10.2    INDEMNIFICATION OF GENVEC. Fuso shall indemnify and hold GenVec and
its Affiliates and their respective directors, officers, employees, agents and
counsel and the successors and assigns of the foregoing (the "GenVec
Indemnitees"), harmless from and against any and all liabilities, damages,
losses, costs or expenses (including reasonable attorneys' and professional fees
and other expenses of litigation and/or arbitration) resulting from a claim,
suit or proceeding brought by a third party against a GenVec Indemnitee, arising
from or occurring as a result of; (i) Fuso's conduct of the

                                     - 19 -
<Page>

Research Program, or (ii) the development, manufacture, marketing and/or
commercialization of any Collaboration Product by Fuso or its Affiliates or
Sublicensees (including without limitation, product liability claims), except,
in each case, to the extent caused by the negligence or willful misconduct of
GenVec.

     10.3    PROCEDURE. A party (the "Indemnitee") that intends to claim
indemnification under this Article 10 shall promptly notify the other party (the
"Indemnitor") in writing of any loss, claim, damage, liability or action in
respect of which the Indemnitee or any of its Affiliates, Sublicensees or their
directors, officers, employees, agents or counsel intend to claim such
indemnification, and the Indemnitor shall have the right to participate in, and,
to the extent the Indemnitor so desires, to assume the defense thereof with
counsel mutually satisfactory to the parties. The indemnity agreement in this
Article 10 shall not apply to amounts paid in settlement of any loss, claim,
damage, liability or action if such settlement is made without the consent of
the Indemnitor, which consent shall not be withheld unreasonably. The failure to
deliver written notice to the Indemnitor within a reasonable time after the
commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such Indemnitor of any liability to the Indemnitee under
this Article 10. At the Indemnitor's request, the Indemnitee under this Article
10, and its employees and agents, shall cooperate fully with the Indemnitor and
its legal representatives in the investigation and defense of any action, claim
or liability covered by this indemnification and provide full information with
respect thereto.

11.  TERM AND TERMINATION

     11.1    TERM. This Agreement shall be effective as of the Effective Date
and, unless otherwise terminated earlier pursuant to the other provisions of
this Article 11, shall continue in full force and effect on a Collaboration
Product-by-Collaboration Product and country-by-country basis until the date
Fuso and its Affiliates and Sublicensees has no remaining royalty obligations in
such country. Following the expiration of royalty obligations in any country,
Fuso shall have a non-exclusive, non-transferable, fully paid license under the
GenVec Know-How solely to commercialize the Collaboration Product in the Field
in such country.

     11.2    TERMINATION FOR CAUSE. Either party may terminate this Agreement in
the event the other party has materially breached or defaulted in the
performance of any of its obligations hereunder, and such default has continued
for sixty (60) days after written notice thereof was provided to the breaching
party by the nonbreaching party. Any termination shall become effective at the
end of such sixty (60) day period unless the breaching party has cured any such
breach or default prior to the expiration of the sixty (60) day period.
Notwithstanding the above, in the case of a failure to pay any amount due
hereunder the period for cure of any such default following notice thereof shall
be ten (10) days and, unless payment is made within such period, the termination
shall become effective at the end of such period.

     11.3    TERMINATION FOR INSOLVENCY. If voluntary or involuntary proceedings
by or against a party are instituted in bankruptcy under any insolvency law, or
a receiver or custodian is appointed for such party, or proceedings are
instituted by or against such party for corporate reorganization or

                                     - 20 -
<Page>

the dissolution of such party, which proceedings, if involuntary, shall not have
been dismissed within sixty (60) days after the date of filing, or if such party
makes an assignment for the benefit of creditors, or substantially all of the
assets of such party are seized or attached and not released within sixty (60)
days thereafter, the other party may immediately terminate this Agreement
effective upon notice of such termination.

     11.4    PERMISSIVE TERMINATION. After the second anniversary of the
Effective Date, Fuso may, at its sole discretion, terminate this Agreement at
any time with ninety (90) days' prior notice.

     11.5    TERMINATION RELATING TO SALES OF COMPETING COLLABORATION PRODUCTS.
GenVec may, at its sole discretion, terminate this Agreement with ninety (90)
days notice in the event of any breach by Fuso of Section 5.6.

     11.6    EFFECT OF BREACH OR TERMINATION.

             11.6.1 ACCRUED OBLIGATIONS. Termination of this Agreement for any
reason shall not release any party hereto from any liability which, at the time
of such termination, has already accrued to the other party or which is
attributable to a period prior to such termination, nor preclude either party
from pursuing any rights and remedies it may have hereunder or at law or in
equity which accrued or are based upon any event occurring prior to such
termination.

             11.6.2 RETURN OF MATERIALS. Upon any termination of this Agreement,
Fuso and GenVec shall promptly return to the other party all materials and
Confidential Information (except as provided in 11.1 above) received from the
other party (except one copy of which may be retained by legal counsel for
archival purposes); provided, however, that the foregoing shall only apply to
GenVec in the event this Agreement is properly terminated by Fuso pursuant to
Section 11.2 or 11.3.

             11.6.3 STOCK ON HAND. In the event this Agreement is terminated for
any reason, Fuso and its Affiliates and Sublicensees shall have the right to
sell or otherwise dispose of the stock of any Collaboration Products then on
hand subject to Articles 3 and 4 and the other applicable terms of this
Agreement.

             11.6.4 LICENSES.

                    (a)  The licenses granted Fuso herein shall terminate in the
event of a termination pursuant to Section 11.2 or 11.3, or any termination of
the Research Program by Fuso prior to the second anniversary of the Effective
Date. In the event of a termination of the Research Program by Fuso after the
second anniversary of the Effective Date, the licenses granted Fuso shall remain
in effect, subject to the terms and conditions herein, with respect to all
Collaboration Products designated by the Steering Committee prior to the
effective date of such termination.

                    (b)  The licenses granted to GenVec in Section 2.3 shall
terminate only in the event of a termination by Fuso pursuant to Section 11.2 or
11.3.

                                     - 21 -
<Page>

                    (c)  If more than one Collaboration Product is being
commercially developed or exploited by Fuso or its Affiliates and Sublicensees
hereunder and GenVec terminates this Agreement pursuant to Section 11.2 due to a
breach relating only to a single Collaboration Product, or pursuant to Section
11.5 due to a particular competing product, then GenVec shall be entitled to
terminate this Agreement only with respect to the applicable Collaboration
Product.

     11.7    SURVIVAL. Sections 2.4, 2.5, 2.6, 5.2.3, 5.3, 5.4, 7.1, 7.2.2,
7.3.2, 11.6 and 11.7 and Articles 4, 8, 9, 10, 12 and 13 shall survive the
expiration or termination of this Agreement for any reason.

12.  DISPUTE RESOLUTION

     12.1    MEDIATION. If a dispute arises out of or relates to this Agreement,
or the breach thereof, and if said dispute cannot be settled through
negotiation, the parties agree first to try in good faith to settle the dispute
by mediation under the Commercial Mediation Rules of the American Arbitration
Association before resorting to arbitration.

     12.2    ARBITRATION. Any dispute under this Agreement (except any dispute
relating to the validity or enforceability of any patent) which is not settled
by mutual consent shall be finally settled by binding arbitration. Such
arbitration shall be conducted in accordance with the International Arbitration
Rules of the Asia/Pacific Center by three (3) arbitrators appointed in
accordance with said rules and held in San Francisco, California. At least one
of the arbitrators shall be an independent expert in pharmaceutical product
development (including clinical development and regulatory affairs). The
arbitrators shall determine what discovery will be permitted, consistent with
the goal of limiting the cost and time which the parties must expend for
discovery; provided the arbitrators shall permit such discovery as they deem
necessary to permit an equitable resolution of the dispute. Any written evidence
originally in a language other than English shall be submitted in English
translation accompanied by the original or a true copy thereof. The costs of the
arbitration including administrative and arbitrators' fees, shall be shared
equally by the parties and each party shall bear its own costs and attorneys'
and witness' fees incurred in connection with the arbitration. A disputed
performance or suspended performances pending the resolution of the arbitration
must be completed within thirty (30) days following the final decision of the
arbitrators or such other reasonable period as the arbitrators determine in a
written opinion. Any arbitration subject to this Article shall be completed
within one (1) year from the filing of notice of a request for such arbitration.
No punitive damages may be granted by the arbitrators. The arbitration
proceedings and the decision shall not be made public without the joint consent
of the parties and each party shall maintain the confidentiality of such
proceedings and decision unless otherwise permitted by the other party. The
parties agree that the decision shall be the sole, exclusive and binding remedy
between them regarding any and all disputes, controversies, claims and
counterclaims presented to the arbitrators. Any award may be entered in a court
of competent jurisdiction for a judicial recognition of the decision and an
order of enforcement.

                                     - 22 -
<Page>

13.  MISCELLANEOUS

     13.1    GOVERNING LAW. This Agreement and any dispute arising from the
performance or breach hereof shall be governed by and construed in accordance
with the laws of the State of California, without reference to conflicts of laws
principles.

     13.2    WAIVER. Neither party may waive or release any of its rights or
interests in this Agreement except in writing. The failure of either party to
assert a right hereunder or to insist upon compliance with any term or condition
of this Agreement shall not constitute a waiver of that right or excuse a
similar subsequent failure to perform any such term or condition.

     13.3    ASSIGNMENT. This Agreement shall not be assignable by either party
to any third party hereto without the written consent of the other party hereto;
except either party may assign this Agreement, without such consent, to (i) an
Affiliate of such party; or (ii) an entity that acquires all or substantially
all of the business or assets of such party to which this Agreement pertains,
whether by merger, reorganization, acquisition, sale, or otherwise and that
agrees in writing to be strictly bound by the terms and conditions of this
Agreement. The terms and conditions of this Agreement shall be binding on and
inure to the benefit of the permitted successors and assigns of the parties.

     13.4    NOTICES. Any notices, requests and other communications hereunder
shall be in writing and shall be personally delivered or sent by international
express delivery service, registered or certified mail, return receipt
requested, postage prepaid, in each case to the respective address specified
below, or such other address as may be specified in writing to the other parties
hereto:

     FUSO:          Fuso Pharmaceutical Industries, Ltd.
                         3-11, 2-Chome, Morinomiya, Joto-ku
                         Osaka 536, Japan
                         Attn: President

     With a copy to:     Director, Research and Development Center

     GENVEC:             GenVec, Inc.
                         65 West Watkins Mill Road
                         Gaithersburg, Maryland 20878, U.S.A.
                         Attn: President

     With a copy to:     Senior Vice President, Corporate Development

     13.5    PERFORMANCE WARRANTY. Fuso and GenVec hereby respectively warrant
and guarantee the performance of any and all rights and obligations of this
Agreement by their Affiliate(s), Sublicensees, and other sublicensees.

     13.6    FORCE MAJEURE. Neither party shall be liable to the other for
failure or delay in the performance of any of its obligations under this
Agreement for the time and to the extent such failure

                                     - 23 -
<Page>

or delay is caused by earthquake, riot, civil commotion, war, hostilities
between nations, governmental law, order or regulation, embargo, action by the
government or any agency thereof, act of God, storm, fire, accident, labor
dispute or strike, sabotage, explosion or other similar or different
contingencies, in each case, beyond the reasonable control of the respective
party. The party affected by force majeure shall provide the other party with
full particulars thereof as soon as it becomes aware of the same (including its
best estimate of the likely extent and duration of the interference with its
activities), and will use its best endeavors to overcome the difficulties
created thereby and to resume performance of its obligations as soon as
practicable. If the performance of any obligation under this Agreement is
delayed owing to a force majeure for any continuous period of more than six (6)
months, the parties hereto shall consult with respect to an equitable solution
including the possible termination of this Agreement.

     13.7    INDEPENDENT CONTRACTORS. Nothing contained in this Agreement is
intended implicitly, or is to be construed, to constitute Fuso or GenVec as
partners in the legal sense. No party hereto shall have any express or implied
right or authority to assume or create any obligations on behalf of or in the
name of any other party or to bind any other party to any contract, agreement or
undertaking with any third party.

     13.8    ADVICE OF COUNSEL. GenVec and Fuso have each consulted counsel of
their choice regarding this Agreement, and each acknowledges and agrees that
this Agreement shall not be deemed to have been drafted by one party or another
and will be construed accordingly.

     13.9    OTHER OBLIGATIONS. Except as expressly provided in this Agreement
or as separately agreed upon in writing between GenVec and Fuso, each party
shall bear its own costs incurred in connection with the implementation of the
obligations under this Agreement.

     13.10   INDEPENDENT RESEARCH. Except as expressly provided for herein or in
the Collaboration Agreement, each party acknowledges and agrees that Fuso and
GenVec shall have the right to engage in their own research and development
activities outside the Research Program. Neither party shall, by virtue of this
Agreement, have any right, title or interest in or to such independent
activities or to the income or profits derived therefrom.

     13.11   SEVERABILITY. In the event that any provisions of this Agreement
are determined to be invalid or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and
effect without said provision. The parties shall in good faith negotiate a
substitute clause for any provision declared invalid or unenforceable, which
shall most nearly approximate the intent of the parties in entering this
Agreement; provided, if the parties are unable to agree on such a substitute
clause and the deletion of the provision held invalid or unenforceable would
produce material adverse financial consequences for one party, such party shall
have the right to terminate the Agreement with one hundred eighty (180) days
notice.

     13.12   PATENT MARKING. Fuso agrees to mark and have its Affiliates and
Sublicensees mark all Collaboration Products they sell or distribute pursuant to
this Agreement in accordance with the applicable statute or regulations in the
country or countries of manufacture and sale thereof.

                                     - 24 -
<Page>

     13.13   FURTHER ASSURANCES. At any time or from time to time on and after
the date of this Agreement, either party shall at the request of the other party
(i) deliver to the requesting party such records, data or other documents
consistent with the provisions of this Agreement, (ii) execute, and deliver or
cause to be delivered, all such consents, documents or further instruments of
assignment, transfer or license, and (iii) take or cause to be taken all such
actions, as the requesting party may reasonably deem necessary or desirable in
order for the requesting party to obtain the full benefits of this Agreement and
the transactions contemplated hereby.

     13.14   TRADEMARKS. Fuso and its Affiliates shall have the right to market
the Collaboration Product under their own labels and trademark(s). All
Collaboration Product packages shall carry the notice "Licensed from GenVec,
Inc." or a similar slogan, in a typeface and size agreed by the parties.

     13.15   FOREIGN CORRUPT PRACTICES ACT. In conformity with the United States
Foreign Corrupt Practices Act, Fuso and its employees and agents shall not
directly or indirectly make any offer, payment, promise to pay, or authorize
payment, or offer a gift, promise to give, or authorize the giving of anything
of value for the purpose of influencing an act or decision of an official of any
government within the Territory or the United States Government (including a
decision not to act) or inducing such official to use his influence to affect
any such governmental act or decision in order to obtain, retain, or direct any
such business.

     13.16   EXPORT LAWS. Notwithstanding anything to the contrary contained
herein, all obligations of GenVec and Fuso are subject to prior compliance with
United States export regulations and such other United States and Japanese laws
and regulations as may be applicable, and to obtaining all necessary approvals
required by the applicable agencies of the government of the United States or
Japan. GenVec and Fuso, respectively, shall each use its best efforts to obtain
such approvals from its own government. Each party shall cooperate with the
other party and shall provide assistance to the other party as reasonably
necessary to obtain any required approvals.

     13.17   APPROVALS. Each party shall be responsible, at its expense, for
obtaining any approvals from its own government which may be required under
applicable law, and shall use its best efforts to obtain all necessary approvals
as soon as possible after the execution of this Agreement.

     13.18   ENTIRE AGREEMENT. This Agreement, including the attached Exhibits,
and the Collaboration Agreement of even date herewith, constitute the entire
agreement between the parties with respect to the subject matter hereof, and
supersede all prior or contemporaneous understandings or agreements, whether
written or oral, between Fuso and GenVec with respect to such subject matter.
Each party specifically agrees that the Collaboration Agreement and the
Commercialization Agreement between the parties, each dated September 26, 1997,
and the Letter Agreement and Amendment of Letter Agreement dated April 1, 2002
and September 9, 2002 respectively, each of which references such agreements,
are hereby terminated as of the Effective Date. Each party acknowledges that, to
its knowledge, the other party performed all its financial and research

                                     - 25 -
<Page>

obligations thereunder. The foregoing shall in no way limit those obligations
that expressly survive the termination of such agreements.

     13.19   HEADINGS. The captions to the several Sections and Articles hereof
are not a part of this Agreement, but are included merely for convenience of
reference only and shall not affect its meaning or interpretation.

     13.20   COUNTERPARTS. This Agreement may be executed in two counterparts,
each of which shall be deemed an original and which together shall constitute
one instrument.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their authorized representatives as of the Effective Date.

FUSO PHARMACEUTICAL                             GENVEC, INC.
INDUSTRIES, LTD.

By:    /s/ Mikio Toda                    By:    /s/ Paul H. Fischer
      -----------------------------            ------------------------

Name:  Mikio Toda                        Name:  Paul H. Fischer
      -----------------------------            ------------------------

Title: President and Representative      Title: President and C.E.O.
       Director                                ------------------------
      -----------------------------

                                     - 26 -<Page>

                                                                   Exhibit 10.10

             THIS SPONSORED RESEARCH AGREEMENT ("Agreement" or "Sponsored
Research Agreement") dated as of April 1, 2002 (the "Effective Date") is entered
into by and between GENVEC, INC., a Delaware corporation ("Sponsor"), and
CORNELL UNIVERSITY, a not-for-profit educational institution having corporate
powers under the laws of the State of New York ("University"), for its Medical
College ("Medical College").

                                   WITNESSETH:

             WHEREAS, the Sponsor and the University have previously entered
into those certain Sponsored Research Agreements effective as of May 18, 1993
and April 1, 1998 (collectively referenced herein as the "Prior Sponsored
Research Agreement"), pursuant to which Sponsor supported preclinical research
and clinical research at the Medical College in connection with Gene Therapy (as
defined in Appendix 1 hereto), which relationship the parties wish to extend;

             WHEREAS, the Gene Therapy research project that is to be conducted
at the Medical College with the support of the Sponsor is to be jointly
supervised by Ronald G. Crystal, M.D. ("Dr. Crystal"), a Professor of Medicine
at the Medical College and a paid consultant and equity holder of the Sponsor
and Chairman of the Sponsor's Scientific Advisory Board, and by the Medical
College's Chairman of the Department of Medicine (currently Ralph L. Nachman,
M.D. ("Dr. Nachman")), all as permitted by and in accordance with applicable
Laws and University Policies (as defined in Appendix 1 hereto);

             WHEREAS, the Sponsor has entered into an Amended and Restated
Exclusive License Agreement, as further amended March 18, 2002, in the form
attached as Exhibit A hereto ("License Agreement") with the Cornell Research
Foundation, Inc. ("Foundation"), a wholly owned subsidiary of the University;

             WHEREAS, the Gene Therapy discoveries and inventions made during
the course of the Sponsored Research (as defined in Appendix 1 hereto), as
contemplated by this Agreement, are of mutual interest and benefit to the
University and to the Sponsor, will further instructional and research
objectives of the University in a manner consistent with its status as a
not-for-profit tax-exempt educational institution, and may constitute benefits
for both the Sponsor and the University (including, without limitation, the
Medical College) through inventions, improvements, and discoveries;

             NOW THEREFORE, in consideration of the premises and mutual
covenants herein contained, the parties hereto agree to the following:

[*]=CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS. OMITTED TEXT IS INDICATED BY A "*".

<Page>

1.   DEFINITIONS

             Capitalized terms used in this Agreement and set forth in Appendix
1 hereto shall have the meanings set forth in such Appendix 1.

2.   SCOPE AND PERFORMANCE OF WORK

             The University shall commence the performance of the Sponsored
Research on the Effective Date, and, concurrently with compliance by Sponsor
with all terms (including payment terms) of this Agreement, agrees to use
reasonable efforts to perform the Sponsored Research in accordance with the
terms and conditions of this Agreement.

3.   PRINCIPAL INVESTIGATORS

     3.1     SUPERVISION OF THE SPONSORED RESEARCH

             As described in the Crystal Appointment Letter, Dr. Crystal and the
Chairman shall jointly supervise the Sponsored Research. Clinical trials with
respect to the Sponsored Research may not take place at the University
(including the Medical College), at affiliated hospitals, clinics, or other
institutions affiliated with the Medical College, under the direction of the
Principal Investigators. Clinical trials at the University (including the
Medical College), at affiliated hospitals, clinics, or other institutions
affiliated with the Medical College, if any, will take place entirely under the
supervision of independent investigators who are not and have not been
associated with the Sponsored Research. The parties hereto acknowledge and agree
that the Crystal Appointment Letter has been approved by the Medical College,
the University, The New York Hospital, and all applicable internal review boards
of such bodies, including, without limitation, those charged with responsibility
for administration of the University's conflict of interest policies, as of the
date of this Agreement, subject, however, to any changes in such approvals and
policies as the University or such other entities or boards may determine to be
necessary or advisable.

     3.2     CHANGE IN PRINCIPAL INVESTIGATORS

             In the event that Dr. Crystal dies, becomes disabled such that he
cannot continue his employment at the Medical College, terminates his employment
at the Medical College, or his employment at the Medical College is otherwise
terminated, either party to this Agreement shall have the option to terminate
this Agreement and the Sponsored Research in the manner provided in Section 8.
If Dr. Nachman dies, becomes disabled such that he cannot continue his
employment at the Medical College, terminates his employment at the Medical
College, or his employment at the Medical College is otherwise terminated, or
otherwise is unable or unwilling to continue to serve as co-Principal
Investigator with respect to the Sponsored Research, the successor to Dr.
Nachman as Chairman shall serve as co-Principal Investigator with Dr. Crystal,
unless the University shall have designated another member of its faculty
reasonably acceptable to Sponsor and to Dr. Crystal to serve as the co-Principal
Investigator with Dr. Crystal; provided, however, that if such Chairman or other
faculty member has any consulting or other commercial relationship with a
competitor of

                                                                             -2-
<Page>

Sponsor in the gene therapy field, the University, upon notice of objection from
Sponsor, shall designate another member of its faculty, reasonably acceptable to
Sponsor and Dr. Crystal, without such relationship, to serve as co-Principal
Investigator.

4.   PERIOD OF PERFORMANCE

             The period of performance under this Agreement will terminate on
April 1, 2004, unless earlier terminated pursuant to this Agreement or extended
by written agreement of the parties.

5.   PAYMENTS

     5.1     SPONSOR PAYMENTS

             The Sponsor agrees to make payments to the University (on behalf of
the Medical College) for certain costs of the Sponsored Research in accordance
with the payment schedule attached as Exhibit B hereto ("Sponsor Payments"),
subject to and in accordance with the terms of this Agreement. Sponsor Payments
shall be used over the term of this Agreement for the rental of space for Dr.
Crystal's laboratory, the purchase or rental of the substantial portion of the
equipment in such laboratory, a portion of Dr. Crystal's salary from the
University, general research support for preclinical feasibility projects, and
related matters, including support of other members of Dr. Crystal's laboratory
(all of whom will be employees of the University). The aggregate amount of the
Sponsor Payments shall be One Million Three Hundred Twenty Thousand Dollars
($1,320,000), unless the parties agree otherwise pursuant to Section 5.2. All
checks (or electronic funds transfers) shall be made payable to Cornell
University Medical College and sent to the address specified in Section 19.6.
Within ninety (90) days after termination of this Agreement, the University
shall submit a final financial report setting forth costs incurred. The report
shall be accompanied by a check in the amount, if any, of the excess of Sponsor
Payments received by the University over costs actually incurred by or on behalf
of the University in connection with the Sponsored Research.

     5.2     ADDITIONAL PAYMENTS

             It is agreed to and understood by the parties that the aggregate
amount of the Sponsor Payments is an estimate of the cost of the Sponsored
Research, but that the Sponsor shall not be liable for any payments or costs in
excess of the Sponsor Payments unless the Sponsor shall have previously agreed
in writing to provide additional funds. Funding for work to be performed during
a period beyond that set forth in Section 4, or for work in addition to the
Sponsored Research, shall be agreed to by the Sponsor and the University in
writing prior to the initiation of any such work.

     5.3     UNIVERSITY BOOKS AND RECORDS

             The University shall maintain records and books of account relating
to this Agreement in accordance with its normal course of business, University
Policies, and prevailing University accounting practices, and shall make such
records and books available to Sponsor upon reasonable notice during normal
business hours, but not more frequently than once every four (4) months.

                                                                             -3-
<Page>

             The University shall maintain scientific records that will properly
reflect all work done, and data and results achieved in the performance of the
Sponsored Research (including all data in the form required under any applicable
governmental regulations) in a manner sufficient to establish the dates of first
conception and reduction to practice of any inventions.

     5.4     SPONSOR PAYMENTS

             Any funds paid to the University pursuant to the Prior Sponsored
Research Agreement which were not expended as of the Effective Date hereof shall
be used to support the Sponsored Research subject to this Agreement. Such funds
shall be additional to the payments due pursuant to Section 5.1, but otherwise
shall be treated as Sponsor Payments for all purposes of this Agreement.

     5.5     OTHER FUNDS

             The University shall not use funds from any commercial third party
to support any aspect of the Sponsored Research without the prior written
consent of Sponsor.

6.   INVENTIONS AND PATENTS

             The Medical College shall disclose all Sponsored Research
Intellectual Property Rights to the Sponsor as promptly as practicable upon
receipt of such disclosure, but in no event later than * after the inventor
discloses it in writing to the Medical College personnel responsible for patent
matters. The Principal Investigators shall ensure that all such Sponsored
Research Intellectual Property Rights are promptly disclosed to the Medical
College in writing. The disclosure to the Sponsor shall be in the form of a
written report and shall identify the inventor(s) and this Agreement as being
that under which such invention was made. Such report shall be sufficiently
complete in technical detail to convey a clear understanding, to the extent
known at the time of the disclosure, of the nature, purpose, operation, and the
physical, chemical, biological, or electrical characteristic of the invention.
To afford the parties a reasonable opportunity to preserve their intellectual
property rights, without the parties' written consent neither the Medical
College nor the Sponsor shall disclose such Sponsored Research Intellectual
Property Rights to third parties for at least * after the date of such
disclosure to the Sponsor pursuant to this Section 6; provided that during such
* period and thereafter the Sponsor may disclose such Sponsored Research
Intellectual Property Rights to a corporate partner of Sponsor which is entitled
to a sublicense of all or part of the Sponsored Research Intellectual Property
Rights, if such corporate partner and Sponsor have a written agreement of
confidentiality consistent with the provisions hereof. Any disclosures made
pursuant to this Section 6 shall also comply with Section 10 hereof with respect
to any proposed publication, sale, or public use of the invention and shall
disclose whether a manuscript describing the invention has been prepared and is
proposed to be submitted for publication or presentation. Title to reported
inventions will be held in accordance with Section 16.1. Within * of receipt of
the invention report, the Sponsor shall notify the University, in writing, that
it elects to license such reported invention to the extent permitted by, and in
accordance with the terms of, the License Agreement. Notwithstanding this
Section 6 or any other provision of this Agreement, however, except to the
extent the same are included within Sponsored Research Intellectual Property
Rights, the parties agree that this Agreement does not authorize or compel the
disclosure to the Sponsor of information

                                                                             -4-
<Page>

regarding research designs, methods, proposals, findings, or similar information
or data of investigators (or other University employees) not employed in Dr.
Crystal's laboratory and under the joint supervision of Dr. Crystal and the
Chairman (even though the Sponsor's funds may have been used to provide
ancillary noninventive services or equipment to such inventor or other
employee).

7.   PROPRIETARY INFORMATION

             The Medical College's acceptance and use of any proprietary
information or proprietary biological materials that may be supplied by the
Sponsor in the course of this research project shall be subject to the
following:

             (i)    The Sponsor shall mark or designate in writing the
information or biological materials as being proprietary to the Sponsor or,
where appropriate, to a sublicensee of Sponsor.

             (ii)   The Medical College retains the right to refuse to accept
any such information or biological materials that it does not consider to be
essential to the completion of the Sponsored Research or that it believes to be
improperly designated, for any reason.

             (iii)  Where the Medical College does accept such information, it
agrees to use reasonable efforts not to publish or otherwise reveal the
information to others outside the Medical College without the permission of the
Sponsor, unless the information has already been published or disclosed, or the
information has already been independently developed, in each case by third
parties or is or are required to be disclosed or delivered by order of a court
of law or regulatory agency, provided that the Medical College seeks
confidential treatment or protective order prior to such disclosure.

             (iv)   Where the Medical College does accept such biological
materials, their use shall be subject to the terms of the Material Transfer
Agreement entered by Sponsor and the Medical College effective December 19, 1996
(the "Material Transfer Agreement"), a copy of which is attached hereto as
Exhibit C.

8.   TERMINATION

     8.1     TERMINATION EVENTS

             This Agreement may be terminated (prior to the expiration of its
term pursuant to Section 4) at any time by one party, upon written notice to the
other party, upon the occurrence of any of the following events:

             (i)    either party may terminate the Agreement if Dr. Crystal
dies, becomes disabled such that he cannot continue his employment at the
Medical College, terminates his employment at the Medical College, or his
employment at the Medical College is otherwise terminated;

             (ii)   either party may terminate the Agreement if, in the
reasonable judgment of the terminating party, termination is necessitated by
reason of a change in Laws; provided, however, that

                                                                             -5-
<Page>

the Sponsor shall not use as a ground of termination such a change which could
be cured by a revision of Dr. Crystal's relationship with the Sponsor;

             (iii)  a party may terminate the Agreement if it has a reasonable
basis to believe that the other party has engaged in unlawful, unethical, or
seriously inappropriate conduct such that continued performance of the Agreement
would affront legitimate interests of the terminating party; or

             (iv)   a party may terminate the Agreement if the other party has
committed a material breach of the terms of this Agreement or the License
Agreement and has failed to remedy such breach within ten (10) days in relation
to a payment-related breach, and thirty (30) days in relation to other breaches,
following written notice thereof. For purposes of this Section 8, a failure by
the Sponsor to make any payment required pursuant to Section 5 shall be deemed a
material breach.

             (v)    In the event that a party intends to terminate the Agreement
under Section 8.1(ii), (iii) or (iv), the party shall give written notice to
that effect to the other party, which notice shall effect forthwith suspension
of future performance of the Agreement. The party so notified may initiate
arbitration under Section 19.5, by filing a request for arbitration with the
American Arbitration Association, not later than ten (10) days thereafter, and
termination shall occur if (a) arbitration is not so initiated, or (b) the
arbitrator finds that termination was reasonable.

     8.2     TERMINATION CONSEQUENCES

             In the event of early termination of this Agreement by the Sponsor
pursuant to Section 8.1, or by the University pursuant to Section 8.1(ii),
(iii), or (iv), the Sponsor shall remit to the University funds in payment of
(a) all internal and external costs and non-cancelable obligations, including
future costs and obligations, incurred as of the date of termination by the
University incident to the Sponsored Research (including, without limitation,
rent, personnel costs, facilities costs, and other costs) until such time as the
University, exercising its best efforts, shall eliminate such costs (or utilize
such personnel and facilities in other endeavors), and (b) any other amounts
that have accrued under this Agreement as of the date of such termination. With
respect to all payments by the Sponsor required by this Section 8.2, in no event
shall the liability of the Sponsor for Sponsor Payments in connection with the
Sponsored Research exceed Six Hundred Sixty Thousand Dollars ($660,000) or such
other amount as the parties hereto have agreed upon pursuant to Section 5. Any
and all Sponsored Research Intellectual Property Rights conceived or reduced to
practice or otherwise developed prior to the effective date of such termination
shall remain subject to the terms of the License Agreement, which shall remain
in effect until and unless terminated under its terms.

9.   PUBLICITY

             The parties acknowledge their mutual intention to announce major
scientific discoveries to the public on a prompt and cooperative basis,
consistent with the terms of this

                                                                             -6-
<Page>

Section 9 and other provisions of this Agreement. The parties agree that neither
the University nor any employee thereof shall in any way promote, or participate
or be used or referred to in connection with the promotion of the Sponsor or any
of Sponsor's products, securities, or marketing efforts, and that neither party
shall use the existence or terms of this Agreement, any results of the Sponsored
Research, or the name of the other party (or any employee or affiliate thereof)
in any public disclosure, advertising, news release, or other statement that is
or may become public or available to a third party, in each case except as and
to the extent (i) required by Laws (including Securities Laws), (ii) permitted
by Section 10, (iii) permitted by Section 6, or (iv) with the prior written
consent of, and only to the extent approved by, the other party (which consent
shall, in the case of the University, be signed by the Dean of the Medical
College and by University counsel). Notwithstanding the above, once a particular
disclosure has been approved, either party may make disclosures which do not
differ materially therefrom without any further consents of the other party;
provided, however, that the disclosing party shall give prior notice of
subsequent disclosures which, in addition to the information contained in the
earlier disclosure, contains information subject to this Agreement which has not
been previously disclosed; and provided, further, that after approval of a
disclosure has been given, the approving party may at any time with written
notice to the other party withdraw its approval of a particular disclosure prior
to its release, which withdrawal shall be effective immediately. With respect to
the requirements of Securities Laws, counsel to the underwriters or placement
agents of Sponsor's securities may advise Sponsor that Sponsor may be required
to disclose material terms of this Agreement and the License Agreement. In such
event, Sponsor shall so notify the University within a reasonable time prior to
such disclosure, and the University shall have the opportunity to dissuade such
counsel of the need for such disclosure. With respect to any such prospective
disclosure, Sponsor shall use its reasonable efforts, unless the University
otherwise consents, not to use the name of the University, and to seek
"Confidential Treatment" under applicable Securities and Exchange Commission
rules and procedures with respect to any terms of this Agreement and the License
Agreement for which the University wishes to obtain confidential treatment.
Laboratory personnel, including Dr. Crystal, will not engage in solicitation of
the sale of securities of Sponsor, but may, to the extent that doing so does
not, in the University's judgment, unreasonably interfere with their work,
participate in connection with the due diligence investigations of potential
investors and underwriters of securities of Sponsor in describing the Gene
Therapy research and may, to the same extent, respond to questions from such
persons.

10.  PUBLICATIONS

     10.1    RIGHT TO PUBLISH; PROCEDURES

             The University shall have the right, subject to compliance with the
provisions of this Agreement, at its discretion to release information or to
publish any material resulting from the Sponsored Research, and the Sponsor
agrees that the Principal Investigators and other researchers engaged in the
Sponsored Research shall be permitted to present at national, regional and other
professional meetings and symposia, and to publish in journals, theses or
dissertations, or other materials of their own choosing, the progress and
results of the Sponsored Research. The University agrees to furnish the Sponsor
with a copy of any proposed written publication at least * in advance of the
submission of such proposed publication or other written description of research
results to a journal, editor or other third party, in order for the Sponsor to
have an opportunity to begin to seek appropriate legal protection for the
subject matter contained in the proposed publication or

                                                                             -7-
<Page>

description. If due to a valid business reason or a reasonable belief by the
non-disclosing Party that a disclosure relating to the Sponsored Research
contains subject matter for which a patent should be sought, then prior to the
expiration of the * period, the non-disclosing party shall so notify the
disclosing party, who shall then delay public disclosure of the information for
an additional period of up to * to permit the preparation of filing of a patent
application on the subject matter to be disclosed or other action to be taken.
The Sponsor shall cooperate with the University and the Foundation, at their
request, in the patenting process.

     10.2    ACKNOWLEDGMENT OF THE SPONSOR

             The Sponsor will be given full credit and acknowledgment for the
support provided to the University in any publication resulting from the
Sponsored Research, to the extent Sponsor consents to such credit or
acknowledgment, or such publication requires the same, or the University desires
to list Sponsor in any reports of University's sponsored research projects.

11.  REPORTS AND CONFERENCES

     11.1    PROGRESS AND FINAL REPORTS TO THE SPONSOR

             The University shall furnish the Sponsor letter reports during the
term of this Agreement summarizing the work conducted with respect to the
Sponsored Research, no more frequently than once every *, but at least once per
year at Sponsor's request. A final written report setting forth and detailing
the accomplishments and significant findings shall be submitted by the
University within * of the termination of this Agreement.

     11.2    MEETINGS BETWEEN THE UNIVERSITY AND THE SPONSOR

             During the term of this Agreement, representatives of the
University will meet with representatives of the Sponsor at times and places
mutually agreed upon to discuss the progress and results, as well as ongoing
plans, or changes therein, of the Sponsored Research to be performed hereunder.
The Sponsor shall reimburse the University for all reasonable out-of-pocket
expenses incurred by the University and University employees in connection with
any such meetings that are held at locations other than the Medical College.

12.  CHANGES

             Anything in this Agreement to the contrary notwithstanding, Sponsor
and the Medical College may at any time amend or extend the Sponsored Research
by mutual written agreement (which, in the case of the Medical College, shall be
signed by the Dean of the Medical College), and incorporate such amendment as an
attachment and exhibit to this Agreement. Such changes may include, but are not
limited to, (i) revising (including, without limitation, additions to or
deletions from) the work included in the Sponsored Research, (ii) revising the
period or schedule of performance under Section 4 or as set forth in Exhibit B,
or (iii) increasing or decreasing the Sponsor Payments. Upon any such change,
the parties shall immediately use their best efforts to take all necessary steps
to comply therewith.

                                                                             -8-
<Page>

13.  SPONSOR MATERIALS

             Upon the request of the Medical College, the Sponsor agrees to
accept the return of unused portions of any drugs, chemicals, and other
materials supplied by the Sponsor in connection with the Sponsored Research or
Biological Materials provided pursuant to the Material Transfer Agreement
("Sponsor Materials"), including the containers in which the Sponsor Materials
are shipped, provided that the Sponsor Materials and containers are properly
labeled. The Sponsor agrees to furnish the Medical College with sufficient
information regarding all such Sponsor Materials to permit reasonable
interpretation of the results obtained in the Sponsored Research and to identify
precautions needed to help protect the health and safety of personnel using the
Sponsor Materials. The Sponsor agrees to indemnify and defend the University
(including, without limitation, the Medical College), affiliated hospitals,
clinics, and other institutions affiliated with the Medical College, and the
officers, trustees, agents, and employees of each of them, and hold them
harmless from any and all injury, illness, death, property damage, claim,
lawsuit, judgment thereon, or cause of action that results either in whole or in
part from the use of the Sponsor Materials (each a "Claim"), not arising from
the indemnified party's gross negligence or willful misconduct, if such use was
pursuant to Sponsor's directions or was reasonable under the circumstances. The
University shall promptly notify Sponsor of any such Claim for which the
University intends to claim indemnification, and cooperate fully with Sponsor
and its attorneys in the investigation, conduct, defense and settlement of any
such Claim.

14.  INDEMNIFICATION

             The Sponsor agrees to indemnify and defend the University
(including the Medical College), and affiliated hospitals, clinics, or other
institutions affiliated with the Medical College, and the officers, trustees,
agents, and employees of each of them, and hold them harmless from any and all
costs, expenses, and damages, not arising from the indemnified party's gross
negligence or willful misconduct, arising out of any injury, illness, death,
property damage, claim, lawsuit, judgment thereon, or cause of action (each, a
"Claim") to the extent that these result either in whole or in part from action
or inaction on the part of, or on behalf of, the Sponsor in connection with the
conduct of the Sponsored Research. The University shall promptly notify Sponsor
of any such Claim for which the University intends to claim indemnification, and
cooperate fully with Sponsor and its attorneys in the investigation, conduct,
defense and settlement of any such Claim.

15.  INSURANCE

             Within thirty (30) days after the date of this Agreement, the
Sponsor shall provide to the University evidence that the Sponsor has liability
insurance of at least five million dollars ($5,000,000). Such evidence shall be
in the form of a certificate of insurance or, in the case of self-insurance, a
letter accompanying the Sponsor's audited financial statements in which an
authorized official of the Sponsor certifies that the Sponsor has sufficient
assets to cover potential costs and losses that might arise in connection with
the Sponsor's obligations hereunder.

                                                                             -9-
<Page>

16.  TITLE TO EQUIPMENT, RESEARCH DATA AND INTELLECTUAL PROPERTY RIGHTS

     16.1    PROPERTY OF THE UNIVERSITY

             Title to all (a) equipment, laboratory animals, and other materials
or property purchased or manufactured in the performance of the Sponsored
Research (collectively, "Research Equipment") funded under this Agreement and
research data (including, without limitation, data contained in any publication
made pursuant to Section 10 hereof and resulting from the Sponsored Research)
shall vest in the University and shall remain the property of the University in
a manner consistent with University Policies and customs with respect thereto,
and (b) any intellectual property first conceived or discovered in the
performance of the Sponsored Research shall vest in accordance with the
then-prevailing United States laws of inventorship. The Sponsor shall have the
right to receive and use, subject to the applicable terms of the License
Agreement, breeding pairs of animals and other biological materials developed in
connection with the Sponsored Research and copies of any research data relating
to the Sponsored Research on reasonable request and notice, and upon
reimbursement by the Sponsor of the University's reasonable costs incurred in
connection with copying and providing such research data, animals and other
biological materials to the Sponsor. Copyright to materials, including computer
software, first created during the performance of the Sponsored Research work
funded under this Agreement shall vest in accordance with the University's
copyright policy, and the Sponsor shall have no rights thereto, except to the
extent provided in the License Agreement.

     16.2    GOVERNMENT RIGHTS

             An agency of the U.S. Government may have certain rights in an
invention first conceived or discovered during the performance of the Sponsored
Research work funded under this Agreement. The University will use reasonable
efforts to perfect its ownership in any invention made with funds provided by
any government agency and to comply with applicable law in maintaining such
rights and to make available to the Sponsor any rights in such invention.

17.  ACKNOWLEDGMENT AND UNDERTAKING RESPECTING DR. CRYSTAL

             Sponsor hereby acknowledges that it has been informed of the terms
and conditions of the employment of Dr. Crystal at the Medical College, as set
forth in the Crystal Appointment Letter (including, without limitation,
paragraphs 1A-N and the other provisions of Appendix A thereto), and Sponsor
agrees that it will use reasonable care such that nothing requested by Sponsor
of Dr. Crystal will violate any of the duties or obligations of Dr. Crystal to
the University. Nothing in this Agreement or in the License Agreement, or in any
agreement, undertaking, or understanding to which the Sponsor is party, shall
impair the rights of the University or the Principal Investigators to determine
the nature of performance of Sponsored Research, or Dr. Crystal's other research
at the University, in a manner consistent with University Policies. The
University undertakes to notify Sponsor of any changes in the terms and
conditions of Dr. Crystal's employment material to Sponsor, in the University's
reasonable judgment.

                                                                            -10-
<Page>

18.  ENFORCEMENT OF UNIVERSITY RULES AND THIS AGREEMENT

             The University shall use its best efforts to enforce observance by
all University personnel engaged in the Sponsored Research with respect to
University Policies. The Sponsor shall cooperate with University in complying
with University Policies and applicable Laws. The University shall use
reasonable efforts to enforce observance, by all University personnel engaged in
the Sponsored Research, of this Agreement.

19.  OTHER PROVISIONS

     19.1    CONTINUED APPLICABILITY OF CRYSTAL APPOINTMENT LETTER

             Nothing in this Agreement shall be deemed to modify or supersede
the Crystal Appointment Letter (including, without limitation, paragraphs 1A-N
and the other provisions of Appendix A thereto), all of which the parties
acknowledge.

     19.2    NO CONFLICTS

             The Sponsor represents and covenants that there are no obligations,
undertakings, representations, warranties, covenants, conditions, rights,
recitals or other statements by or applicable to the University, Dr. Crystal, or
the Sponsored Research (collectively, "Terms") contained in any of its
arrangements, understandings or agreements with Dr. Crystal (collectively, the
"Other Arrangements") that Conflict with any Terms of this Agreement. For
purposes of this Agreement, the word "Conflict" shall include, without
limitation, any case in which (1) performance of a Term in one agreement would
result in a breach or violation of any present or future agreement or
obligation, written or oral, in connection with a Term in another agreement, and
(2) a Term in one agreement could not be carried out as a legal and/or practical
matter consistently with a Term of another agreement absent an amendment to,
waiver of, or potential liability under, such other agreement. The Sponsor
covenants and agrees that it will not knowingly cause or permit any Conflict to
exist between a Term of this Agreement, on the one hand, and a Term of any Other
Agreement, on the other hand, and that, insofar as any Conflict exists at any
time, the Sponsor will seek to cause such Conflicting Term in the Other
Agreement to be waived, amended or rendered null and void, to the extent
necessary to remedy the Conflict.

     19.3    NO AGENCY

             Neither party is authorized or empowered to act as an agent for the
other for any purpose. Neither party shall, on behalf of the other, enter into
any contract, warranty, or representation as to any matter. Neither party shall
be bound by the acts or conduct of the other.

     19.4    FORCE MAJEURE

             Neither the University nor the Sponsor shall be liable for any
failure to perform as required by this Agreement, to the extent such failure to
perform is caused by any reason beyond the control of the University or the
Sponsor, as applicable, or by reason of any of the following occurrences, labor
disturbances or labor disputes of any kind, accidents, failure of any
governmental approval required for full performance, civil disorders or
commotions, acts of aggression, floods,

                                                                            -11-
<Page>

earthquakes, acts of God, energy or other conservation measures, explosion,
failure of utilities, mechanical breakdowns, material shortages, disease or
other such occurrences (collectively, "Force Majeure Conditions"); provided,
however, that nothing in this Section 19.4 shall excuse any delay or failure on
the part of the Sponsor to make the Sponsor Payments on a timely basis pursuant
to the terms of this Agreement. In the event of any delayed or excused
performance pursuant to this Section 19.4, the party or parties whose
performance was delayed or excused shall use reasonable efforts to perform as
promptly and fully as practicable, and the parties shall take all other
reasonable and cooperative steps to effectuate the transactions contemplated by
this Agreement. If one or more Force Majeure Conditions cause the University to
be unable to conduct Sponsored Research for at least two consecutive weeks, the
obligation of Sponsor to make Sponsor Payments shall be diminished by twelve
thousand six hundred ninety two dollars and thirty cents ($12, 692.30) for each
such week. In the event that there are more than twelve (12) consecutive such
weeks, either party may elect to terminate the Agreement under the provisions of
Section 8.1(iv), as if such circumstance were a material breach thereunder and
as if the University were the terminating party thereunder.

     19.5    ARBITRATION

             Any dispute arising out of or relating to this Agreement or any
breach of this Agreement, including, without limitation, any disagreement by the
terminated party with respect to termination of this Agreement pursuant to
Sections 8.1(ii), (iii) or (iv) shall be submitted to and determined in binding
arbitration, which shall be conducted in accordance with the then-current rules
and procedures of the American Arbitration Association, subject to the
provisions of this Section 19.5. The arbitration shall be conducted before and
by a single neutral arbitrator with relevant expertise selected by the parties.
If the parties have not selected an arbitrator within thirty (30) days after
delivery to the other party of one party's written demand for arbitration, the
arbitrator shall be selected by the American Arbitration Association pursuant to
then-current rules of that Association. The arbitrator shall have authority to
fashion such just, equitable and legal relief as he, in his sole discretion, may
determine, including, without limitation, specific performance, injunctive or
other equitable relief. Each party shall bear all its own expenses of
arbitration and shall equally share the costs (i.e., arbitrators fees and
administrative charges) of conducting the arbitration. All arbitration
proceedings shall be conducted in New York, New York. The parties shall abide by
the terms of any arbitration award as final and binding under the prevailing
rules of said Association, and judgment upon the award may be had in any court
having jurisdiction. The duty to arbitrate shall survive the cancellation or
termination of this Agreement.

     19.6    NOTICES

             All notices, demands, requests or other communications which may be
or are required to be given, served, or sent by the University or the Sponsor
pursuant to this Agreement shall be in writing and shall be hand delivered
(including delivery by courier), sent by recognized overnight courier service,
mailed by first-class, registered or certified mail, return receipt requested,
postage prepaid, or transmitted by telegram, telex or facsimile transmission,
addressed as follows:

             (i)    If to the University:

                                                                            -12-
<Page>

                    Senior Associate Dean for Research
                     and Sponsored Programs
                    Cornell University Medical College
                    Room A131
                    1300 York Avenue
                    New York, New York 10021

                    Telephone: (212) 746-6020
                    Facsimile: (212) 746-6938

                    With a copy (which shall not constitute notice) to:

                    Office of University Counsel
                    Cornell University Medical College
                    1300 York Avenue
                    New York, New York 10021

                    Telephone: (212) 746-0463
                    Facsimile: (212) 746-0495

             (ii)   If to the Sponsor:

                    President
                    GENVEC, INC.

                    65 West Watkins Mill Road
                    Gaithersburg, Maryland 20878

                    With a copy to: Vice President, Corporate Development

                    Telephone: (240) 632-0740
                    Facsimile: (240) 632-0735

Notwithstanding the foregoing, each party may designate by notice in writing a
new address or facsimile number to which any notice, demand, request, or
communication may thereafter be so given, served, or sent. Each notice, demand,
request, or communication which shall be delivered, sent, mailed, or transmitted
in the manner described above, shall be deemed sufficiently given, served, sent,
or received for all purposes at such time as it is delivered to the addressee
(with an affidavit of personal delivery, the return receipt, the delivery
receipt, or (with respect to a telex or facsimile) the answer back being deemed
conclusive but not exclusive evidence of such delivery) or at such time as
delivery is refused by the addressee upon presentation.

     19.7    SURVIVAL

             It is the express intention and agreement of the parties that all
covenants, agreements, statements, representations, warranties and indemnities
made in this Agreement shall survive the execution and delivery of this
Agreement.

                                                                            -13-
<Page>

     19.8    WAIVER

             Neither the waiver by either party of a breach of or a default
under any of the provisions of this Agreement, nor the failure of a party, on
one or more occasions, to enforce any of the provisions of this Agreement or to
exercise any right, remedy, or privilege hereunder shall thereafter be construed
as a waiver of any subsequent breach or default of a similar nature, or as a
waiver of any such provisions, rights, remedies, or privileges hereunder.

     19.9    EXERCISE OF RIGHTS

             No failure or delay on the part of a party in exercising any right,
power, or privilege hereunder and no course of dealing between the parties shall
operate as a waiver thereof; nor shall any single or partial exercise of any
right, power, or privilege hereunder preclude any other or further exercise
thereof or the exercise of any other right, power, or privilege. The rights and
remedies herein expressly provided are cumulative and not exclusive of any other
rights or remedies which a party would otherwise have at law or in equity or
otherwise.

     19.10   BINDING EFFECT

             Subject to the provisions hereof restricting assignment, this
Agreement shall be binding upon and shall inure to the benefit of the parties
and their respective successors and permitted assigns.

     19.11   ASSIGNMENT

             This Agreement shall not be assigned by either party without the
prior written consent of the other party; provided, however, that the Sponsor
may assign this Agreement upon a merger or sale of all or substantially all of
the Sponsor's assets to the Sponsor's successor in business if such assignment
is approved by the University, such approval not to be unreasonably withheld.
Notwithstanding the foregoing, no assignment of this Agreement shall be valid
unless and until the Sponsor and the proposed assignee sign and deliver to the
University a written agreement, reasonably satisfactory to the University,
pursuant to which such assignee assumes and agrees to be fully responsible for
all obligations and liabilities of the Sponsor under this Agreement.

     19.12   ENTIRE AGREEMENT

             This Agreement and the License Agreement (including all exhibits
and appendices to each such agreement) and the Crystal Appointment Letter
contain the entire agreement between the parties with respect to the
arrangements contemplated hereby and thereby and supersede any and all prior
understandings or agreements between the parties with respect to such
arrangements; provided, the terms of the Material Transfer Agreement shall not
be amended or effected in any way by the execution of this Agreement or the
License Agreement. No amendments or changes to this Agreement shall be effective
unless made in writing and signed by the Dean of the Medical College and
authorized representatives of the Sponsor. All correspondence regarding terms of
this Agreement shall be sent as specified in Section 19.6.

     19.13   PRONOUNS

                                                                            -14-
<Page>

             All pronouns and any variations thereof shall be deemed to refer to
the masculine, feminine, neuter, singular, or plural, as the identity of the
person or entity may require.

     19.14   HEADINGS

             Article and Section headings contained in this Agreement are
inserted for convenience of reference only, shall not be deemed to be a part of
this Agreement for any purpose, and shall not in any way define or affect the
meaning, construction of scope of any of the provisions hereof.

     19.15   GOVERNING LAW

             This Agreement, the rights and obligations of the parties hereto,
and any claims or disputes relating thereto, shall be governed by and construed
in accordance with the laws of the State of New York (but not including the
choice of law rules thereof).

     19.16   NONDISCRIMINATION

             The University and the Sponsor shall not discriminate against any
employee or applicant for employment because of race, religion, national origin,
sex, age, or physical limitation.

     19.17   EXECUTION IN COUNTERPARTS

             This Agreement may be executed in as many fully executed
counterparts as may be convenient.

                                                                            -15-
<Page>

          IN WITNESS WHEREOF, the parties and persons named below have executed
this Agreement, or caused this Agreement to be executed on their behalf, as of
the date first set forth above.

GENVEC, INC.                                CORNELL UNIVERSITY, FOR ITS
                                            MEDICAL COLLEGE

By: /s/ Paul Fischer, Ph.D.                 By: /s/ Steven P. Rosalie
    --------------------------------           -------------------------------
    Paul Fischer, Ph.D.
    President

Acknowledged and agreed as to roles as
Principal INVESTIGATORS:

Ronald G. Crystal, M.D.

Chairman of the Department of Medicine of the Medical College

By: Ralph L. Nachman, M.D.

                                                                            -16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]